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Influence Of Acetyl-Coa Metabolism On Histone Acetylation And Cancer 
Abstract 
Cancer cells increase nutrient uptake to support viability and proliferation. The influx of nutrients alters 
intermediary metabolite levels, and compelling evidence shows that metabolite availability impacts cell 
functions through altering chromatin modifications and downstream gene expression. One such 
metabolic intermediate is acetyl-CoA, as the concentration of acetyl-CoA is positively correlated with 
histone and non-histone protein acetylation. Histone acetylation is emerging as a nutrient-sensitive 
process, conferring gene expression changes in response to nutrient availability. In this thesis, we 
examined the impact of acetyl-CoA metabolism on the epigenome. We established that histone 
acetylation is sensitive to acetyl-CoA concentrations, which are dynamically regulated by glucose 
availability. This dynamic increase in histone acetylation induces the expression of cancer-promoting 
genes. We hypothesized that oncogene activation could lead to increased histone acetylation through 
reprogrammed metabolism. In two mouse models of cancer, histone acetylation increased upon 
oncogene activation. Additionally, histone acetylation was positively correlated with phosphorylated AKT 
in human prostate tumors and glioma. To test whether AKT regulates histone acetylation through 
metabolic changes, we utilized glioblastoma cell lines expressing constitutively active AKT and found that 
AKT promotes histone acetylation in nutrient-limited conditions. Mechanistically, this occurs partly 
through AKT-mediated phosphorylation of ACLY at serine 455, increasing ACLY activity. These studies 
reveal a novel role for AKT-driven metabolic changes on global histone acetylation in cancer cells. To 
better understand how concentrations of acetyl-CoA could lead to differential gene expression, we 
investigated a subset of acetyl-CoA regulated genes. Under conditions in which intracellular acetyl-CoA is 
abundant, glioma cells upregulate expression of adhesion and migration genes, increase transwell 
migration, adhere better to ECM, and are efficient in wound healing. Genetic deletion or biochemical 
inhibition of acetyl-CoA generating enzyme, ACLY, abrogates nutrient-dependent adhesion and migration. 
We postulated that specificity for regulation of migration related gene expression would be achieved 
through regulation of transcription factors. Using computational analysis of our acetyl-CoA gene set, 
NFAT1 was predicted as the top transcription factor in promoting these genes. Through fluorescent single 
cell analyses, we find that acetyl-CoA triggers calcium oscillations that allow for NFAT1 nuclear 
localization. These findings suggest that that acetyl-CoA availability is differentially regulated in cancer 
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INFLUENCE OF ACETYL-COA METABOLISM ON EPIGENETICS AND CANCER  
Joyce V. Lee 
Kathryn E. Wellen, Ph.D. 
Cancer cells increase nutrient uptake to support viability and proliferation. The influx of 
nutrients alters intermediary metabolite levels, and compelling evidence shows that 
metabolite availability impacts cell functions through altering chromatin modifications 
and downstream gene expression. One such metabolic intermediate is acetyl-CoA, as the 
concentration of acetyl-CoA is positively correlated with histone and non-histone protein 
acetylation. Histone acetylation is emerging as a nutrient-sensitive process, conferring 
gene expression changes in response to nutrient availability. In this thesis, we examined 
the impact of acetyl-CoA metabolism on the epigenome. We established that histone 
acetylation is sensitive to acetyl-CoA concentrations, which are dynamically regulated by 
glucose availability. This dynamic increase in histone acetylation induces the expression 
of cancer-promoting genes. We hypothesized that oncogene activation could lead to 
increased histone acetylation through reprogrammed metabolism. In two mouse models 
of cancer, histone acetylation increased upon oncogene activation. Additionally, histone 
acetylation was positively correlated with phosphorylated AKT in human prostate 
tumors and glioma. To test whether AKT regulates histone acetylation through metabolic 
changes, we utilized glioblastoma cell lines expressing constitutively active AKT and 
found that AKT promotes histone acetylation in nutrient-limited conditions. 
Mechanistically, this occurs partly through AKT-mediated phosphorylation of ACLY at 




metabolic changes on global histone acetylation in cancer cells. To better understand 
how concentrations of acetyl-CoA could lead to differential gene expression, we 
investigated a subset of acetyl-CoA regulated genes. Under conditions in which 
intracellular acetyl-CoA is abundant, glioma cells upregulate expression of adhesion and 
migration genes, increase transwell migration, adhere better to ECM, and are efficient in 
wound healing. Genetic deletion or biochemical inhibition of acetyl-CoA generating 
enzyme, ACLY, abrogates nutrient-dependent adhesion and migration. We postulated 
that specificity for regulation of migration related gene expression would be achieved 
through regulation of transcription factors. Using computational analysis of our acetyl-
CoA gene set, NFAT1 was predicted as the top transcription factor in promoting these 
genes. Through fluorescent single cell analyses, we find that acetyl-CoA triggers calcium 
oscillations that allow for NFAT1 nuclear localization. These findings suggest that that 
acetyl-CoA availability is differentially regulated in cancer cells and contributes to 
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CHAPTER 1:  
INTRODUCTION  
1.1  Cancer Metabolism 
The metabolism of a cancer cell is distinct from benign, quiescent cells. Cell 
proliferation requires energy and biomass, which is a reason why cancer cells consume 
more glucose than quiescent normal cells in our body.  This altered metabolism is driven 
by genetic mutations in the cancer cell. Study of these changes aids in our understanding 
of how metabolism contributes to tumor growth.   
1.1.1 Reprogrammed metabolism in cancer cells 
In 1924, Otto Warburg observed that cancer cells metabolized more glucose than 
normal cells. Warburg documented that cancer cells tend to convert glucose into lactate 
under aerobic conditions, not typical of normal cells.  By determining the amount of 
lactate produced per hour, he estimated that through “fermentation” (glycolysis), cancer 
cells could produce as many energy equivalents as cells undergoing full utilization of 
glucose through “respiration” (mitochondrial oxidative phosphorylation). This finding 
was perplexing because normal cells obtain much more energy by completing oxidative 
phosphorylation than by glycolysis alone (Warburg, 1956).  Why would cancer cells opt 
for a less efficient metabolism? Warburg proposed that proliferative tumor cells had lost 
their oxidative capacity resulting in their dependence on high glycolysis. However, 
decades later, the carefully analysis of highly proliferative cancer cell lines generated 




in (Moreno-Sanchez et al., 2007)], leaving an explanation for Warburg’s observation 
elusive.   
In subsequent years, leading researchers in the field proposed plausible 
explanations. Rather than viewing this process as purely concerning energy production, 
or generation of adenosine 5′-diphosphate (ATP), perhaps proliferating cells have 
important metabolic requirements that extend beyond ATP production (Vander Heiden 
et al., 2009, DeBerardinis et al., 2008, Ward and Thompson, 2012). Fundamentally, a 
dividing cell must replicate all of its organelles, DNA, cellular membranes to create a 
viable daughter cell. To do this, some glucose must be diverted to form intermediates 
needed for biosynthetic pathways, such as acetyl-CoA for fatty acids, glycolytic 
intermediates for nonessential amino acids, and ribose for nucleotides. The high rate of 
glycolysis allows cancer cells to support biosynthetic processes and energy production 
during rapid proliferation.  
Mitochondria oxidative phosphorylation in cancer cells continue to produce 
metabolites in the tricarboxylic acid (TCA) cycle.  However, while normal non-
proliferating cells rely on the TCA cycle to generate ATP to support their normal 
homeostatic functions, proliferative cells will utilize their TCA cycle intermediates for 
biosynthesis of different macromolecules required for cell division and contributing to 
tumor growth, a process called anaplerosis. For example, under nutrient-rich conditions, 
mitochondrial citrate is transferred out to the cytosol and converted acetyl-CoA, the 
primary building block for lipid synthesis and cholesterol, and OAA, by the enzyme ATP-
citrate lyase (ACLY) (Hatzivassiliou et al., 2005, Parlo and Coleman, 1984). OAA can be 




nucleotides. Rather than relying on mitochondria for ATP synthesis, cancer cells utilize 
the metabolites to support biosynthesis of macromolecules required for proliferation 
(Figure 1).  
1.1.2 Cancer driving mutations rewire metabolism 
The human blood supply provides a constant supply of nutrients. Normal cells 
are instructed to take up nutrients from their environment to support homeostatic 
processes. Uncontrolled proliferation does not occur because nutrient uptake is tightly 
controlled by growth factor signaling. Genetic mutations disrupt this strict regulation, 
allowing cells to overcome growth factor dependence. Mutations that lead to 
constitutively active receptor-initiated signaling pathways allow cancerous cells to take 
up and metabolize nutrients that both promote cell survival and fuel cell growth. These 
oncogenic mutations allow for the uptake of nutrients, particularly glucose, that give 
them the metabolic independence to support cellular programs for growth and 
proliferation. 
One such pathway that is altered is PI3K/Akt signaling [reviewed in (Luo et al., 
2003)]. This pathway is typically responsive to growth factors binding to surface 
receptors, such as EGFR, which signals downstream activation of PI3K, and activating 
phosphorylation of phosphatidylinositol and recruitment of serine theronie kinase Akt.  
In normal cells, activation of the PI3K system is tightly controlled by dephosphorylation 
of phosphatidylinositol species by the phosphatase PTEN. However, mutations that lead 
to the loss of PTEN function allows cancer cells to increase the surface expression of 




[reviewed in (DeBerardinis et al., 2008, Vander Heiden et al., 2009, Ward and 
Thompson, 2012)]. Furthermore, Akt drives glycolysis and lactate production (Elstrom 
et al., 2004b, Plas et al., 2001, Rathmell et al., 2003) and to support synthesis of 
macromolecules in cancer cells by stimulating lipogenic genes and lipid synthesis (Bauer 
et al., 2005). Aberrant activation of many other oncogenes (mTORC1, MAPK, EGFR, 
Ras, HER2/neu, c-myc, and others) or loss of tumor suppressors (VHL, TSC, LKB1, p53, 
and others) also drive metabolic changes, but will not be described in this thesis.  
1.2  Epigenetics and Metabolism 
There is a growing interest in understanding how the environment contributes to 
disease progression. Epigenetic enzymes tightly control the cellular programs that are 
executed in the cell. They are master regulators of the genes programs that should be 
switched on or off. How the environment impacts this switch has been of great interest. 
While nutritional availability largely serves as a fuel source for growing cells, it is 
understood that the metabolites that result from consumption of macronutrients 
contributes another layer of control to epigenetic regulation.    
1.2.1 Cancer Epigenetics 
Epigenetic modifications are one way cells control the transcriptional programs. 
Chromatin modifications work together to control the expression of genes encoded in 
DNA. While a person’s genome is completely identical in the entire body, epigenetic 
regulators provide information on what cell type or function a cell should perform.  
Furthermore, epigenetic regulation of gene expression allows cells to adapt and 




Sassone-Corsi, 2016). This information is relayed in the “histone code” (Jenuwein and 
Allis, 2001, Berger, 2007), which defines certain marks on histone tails as gene 
transcription activating or repressing. While histone methylation on lysine tails can be 
either transcription activating or transcription repressing, acetylation generally “codes” 
for transcription activation. The relationship of these modifications makes up the 
“epigenetic landscape” (Goldberg et al., 2007, Waddington, 1957) that controls the 
manifestation of the genome, which is often deeply altered in diseases such as cancer 
(Jones et al., 2016).     
Human cancer cells are driven by genetic alterations as well as global epigenetic 
abnormalities. These genetic and epigenetic changes contribute to cancer development. 
Human cancers have many global epigenetic abnormalities. For example, we know that 
acetylation and methylation are deeply altered on a global level and large correlations 
studies have been performed to identify how these epigenetic changes correlate with 
prognosis (Chervona and Costa, 2012). However, we do not fully understand how much 
these changes contribute to progression. Notably, these epigenetic modifications are 
reversible. To begin to understand this, it is vital to understand how cancer epigenetics is 
regulated. 
Epigenetic control of gene expression is governed by the activity of “writers” and 
“erasers” of histone marks.  Expression levels of writers and erasers are frequently 
altered in cancer and thus many drug targets include targeting these epigenetic enzymes 
(Jones et al., 2016). However, one may consider the cofactors required for epigenetic 
enzymes to catalyze their reactions often come from metabolism. A less studied but 




macromolecules, which is often deregulated in cancer. Perhaps information about a cell’s 
metabolic state can be assimilated into the regulation of epigenetics and transcription 
(Lu and Thompson, 2012b).  
1.2.2 Metabolite regulation of chromatin 
Many enzymes that regulate post-translational modifications on proteins rely on 
metabolites as co-factors, and in some cases, the activities of these enzymes can be 
regulated by availability of their metabolite co-factors.  This is true in the case of sirtuin 
deacetylases (class III KDACs), which utilize NAD+ as a co-factor to remove acetylation 
from proteins and are activated as the NAD+/NADH ratio rises, as occurs during 
nutrient deprivation (Houtkooper et al., 2012).  
In certain cases, it is already established that metabolites regulate the cancer cell 
epigenome. Tumors with IDH1/2 mutations, for example, generate high levels of (R)-2-
hydroxyglutarate, which interferes with normal activities of α-ketoglutarate-dependent 
enzymes such as tet-methylcytosine dioxygenase 2 (TET2), increasing global methylation 
and resulting in epigenetic and transcriptional deregulation (Lu et al., 2012).  
Even beyond pathological circumstances such as this, accumulating evidence 
indicates that metabolic modulation of signaling, transcription, and chromatin can 
dramatically impact cellular activities. Metabolites can thus exert dual functions in 
providing both building blocks and instructions to the cell. There are many examples of 
posttranslational histone modifications that rely on metabolites such as methylation, 




be described in detail in this thesis [reviewed in  (Sabari et al., 2017, Kinnaird et al., 
2016, Lu and Thompson, 2012b)] 
Emerging at the forefront of such regulation is acetyl-CoA, a metabolite that plays 
key roles in glucose, amino acid, and lipid metabolism, but is also required for 
posttranslational modification on lysine acetylation and for N-terminal acetylation. 
Studies in yeast have provided evidence that acetyl-CoA levels may fluctuate within a 
range to limit the activity of the lysine acetyltransferase (KAT) Gcn5 (Cai et al., 2011), 
based on its dissociation constant (Kd) for acetyl-CoA (8.5 µM). While mammalian 
concentrations of acetyl-CoA have been determined (see Chapter 3), it is noteworthy that 
many KATs, including human GCN5 and p300/CBP, are subject to product inhibition by 
free coenzyme A (CoASH), indicating that the acetyl-CoA/CoASH ratio could be the 
relevant regulator of KAT activity instead of absolute levels of acetyl-CoA (see Chapter 
3).  
1.3 Acetyl-CoA and the regulation of gene expression 
1.3.1 Acetyl-CoA at metabolic crossroads 
Acetyl-CoA is compartmentalized into mitochondrial and nuclear-cytoplasmic 
pools in eukaryotic cells, and these pools are functionally distinct (Takahashi et al., 
2006).  The nuclear-cytoplasmic level of acetyl-CoA in mammalian cells is established 
primarily by the combined actions of two enzymes: ATP-citrate Lyase (ACLY), which 
converts nutrient-derived citrate into acetyl-CoA and oxaloacetate, and acetyl-CoA 
synthetase 2 (ACSS2), which utilizes acetate for acetyl-CoA synthesis (Wellen and 




fatty acid oxidation, amino acid metabolism, the TCA cycle, and lipid synthesis, 
suggesting that acetyl-CoA may be an ideal metabolite for the cells to sense their nutrient 
status (Figure 2). Indeed, glucose-dependent production of acetyl-CoA has been shown 
to regulate global levels of histone lysine acetylation in both yeast and mammals (Friis et 
al., 2009, Wellen et al., 2009).  
Nuclear-cytoplasmic acetyl-CoA production is impacted by metabolic state in a 
complex manner.  ACLY is important for continuous production of extra-mitochondrial 
acetyl-CoA in mammalian cells in nutrient rich conditions (Wellen et al., 2009). ACLY is 
overexpressed in several cancers, including those of the lung, prostate, bladder, breast, 
liver, stomach, and colon (Chypre et al., 2012). Knockdown of ACLY impairs cancer cell 
proliferation (Bauer et al., 2005, Hatzivassiliou et al., 2005). ACLY is also subject to 
allosteric activation by sugar phosphates, and ACLY phosphorylation at Ser455, a site 
regulated by AKT and protein kinase A, enhances its activity in vitro assays (Potapova et 
al., 2000).  Hence, ACLY may serve as an integration point for signaling and metabolic 
cues when metabolic conditions are favorable (Figure 3).   
Alternatively, ACSS2 may become more active when nutrients are scarce, since it 
is deacetylated by SIRT1, allowing for its activation (Hallows et al., 2006). For example, 
under hypoxia, acetate supplementation to cancer cell lines activated expression of 
lipogenic genes, which occurred with acetylation of lysine 9, 27, and 56 on histone H3 
(Gao et al., 2016).  ACSS2 has also been linked to the development and progression of 




1.3.2 Nutrient sensitive histone acetylation and gene expression 
Acetyl-CoA availability has been shown to regulate global levels of histone lysine 
acetylation and alter of gene expression in both yeast and mammals. Pivotal work linking 
metabolism and histone acetylation in mammalian cells was first demonstrated in mouse 
adipocytes (Wellen et al., 2009), establishing that acetyl-CoA can be limiting in the cell 
when glucose is low or when acetyl-CoA producing enzyme ACLY expression is reduced 
in the cell. These changes led to global reduction in histone acetylation (H3K9,14ac; 
H4K5,8,12,16ac) and reduced adipocyte specific gene expression, leading to defective 
cellular differentiation. These effects were all rescued with media supplementation of 
acetate, indicating that cells could sense acetyl-CoA availability to promote these 
processes.  
In Saccharomyces cerevisiae, histone acetylation increased in response to an 
increase of acetyl-CoA when yeast cells were stimulated to enter their metabolic cycle 
(Cai et al., 2011, Kuang et al., 2014). In the middle of the OX (oxidative) phase, acetyl-
CoA began to rise and continued to rise until the middle of the RB (reductive building) 
phase, the phase for cell division. During this time, global histone acetylation on several 
H3 and H4 lysine tails was also the highest. Using genome-wide assessment of H3K9 
acetylation, the authors demonstrated the acetylation was enriched near growth genes 
and was dependent on generation of acetyl-CoA (Cai et al., 2011). Using this system, 
subsequent studies identified distinct histone acetylation peaks that occur across the 
yeast metabolic cycle (Kuang et al., 2014). H3K9ac, H3K14ac and H4K5ac all appeared 
in parallel with the RNA-seq peak (Kuang et al., 2014). Of note, H3K14ac and H4K5ac 




intracellular acetyl-CoA, hinting at differential nutrient sensitivities of chromatin-
modifying enzymes.   
While direct histone acetylation is one mode of gene regulation, acetyl-CoA 
regulation of transcription factor activity, which could also contribute to acetyl-CoA 
dependent gene expression, is relatively less well explored. It is clear that thousands of 
proteins are acetylated including metabolic enzymes and epigenetic modifying enzymes 
(Zhao et al., 2010, Choudhary et al., 2009, Kim et al., 2006). Many metabolic enzymes 
are acetylated in response to glucose availability (Zhao et al., 2010), and it’s important to 
note that not all proteins are differentially acetylated in response to acetyl-CoA. For 
example, while histone acetylation is ACLY dependent, acetylation of p53 and tubulin are 
not reduced upon ACLY silencing in colorectal carcinoma cell line HCT116 (Wellen et al., 
2009).   This supports the idea that certain processes may be more sensitive to nutrients 
than others. Acetyl-CoA availability can impact transcription factors is potentially on 
protein stability, with acetylation and ubiquitination on the same lysine promoting 
opposing effects on the protein stability, as seen in p53 (Li et al., 2002), NFkB (Li et al., 
2012), and Smad7 (Gronroos et al., 2002). Whether these acetylation sites are nutrient 
regulated is of great interest. Few cases of nutrient-dependent transcription factor 
localization have been documented. Glucose-dependent acetylation can regulate b-
catenin (Chocarro-Calvo et al., 2013). Additionally, ACSS2-dependent acetylation 
controls HIF2a regulation of EPO gene expression (Xu et al., 2014). While nutrient-
dependent acetylation of metabolic proteins can coordinate multiple signaling pathways 
to adapt cells to changes in stimuli, understanding the mechanisms of acetyl-CoA guided 




1.4 Hypothesis and Aims  
It is becoming increasingly apparent that acetyl-CoA sits at the hub of both 
metabolic and signaling processes within the cell, as its concentrations are modulated by 
both extracellular nutrient availability and growth factor signaling. The points outlined 
in this thesis will shed light on how acetyl-CoA contributes to these processes for tumor 
growth and survival. 
1.4.1 Sensing levels of acetyl-CoA 
Given that nutrient availability positively correlates with histone acetylation and 
expression of growth-related genes in yeast, we hypothesize that cancer cells also rely on 
nutrient-derived acetyl-CoA for histone acetylation and gene expression. In Chapter 3, 
we characterize histone acetylation in several cancer cell lines and determine the genes 
that are sensitive to acetyl-CoA availability. Secondly, we measure the concentrations of 
acetyl-CoA in mammalian cells, determining the absolute concentrations of acetyl-CoA 
in the cell to understand whether mammalian cellular concentrations of acetyl-CoA are 
within the range of known dissociations constants of KAT enzymes. Additionally, we 
explore whether acetyl-CoA:CoA ratio can regulate histone acetylation in vitro.   
1.4.2 Oncogene induced changes in acetyl-CoA regulated histone acetylation 
 It has also become increasingly clear that certain post-translational modifications 
are sensitive to metabolite availability, raising the possibility that metabolic alterations 
in cancer cells could have a profound influence on signal transduction and epigenetics. 




histone acetylation is high in AKT-driven cancer cells through increased glucose uptake 
and phosphorylation of ACLY (Figure 3).  In Chapter 3, we determine whether AKT 
activation leads to increased histone acetylation using in vivo models of cancer and 
patient samples. we also determine the mechanism for how AKT promotes histone 
acetylation.  
1.4.3 Metabolite directed changes in cell behavior 
In Chapter 4, we investigate the mechanisms by which acetyl-CoA concentrations 
modulate gene expression. From a list of top acetyl-CoA regulated genes identified by 
RNA-sequencing, we hypothesize that the availability of acetyl-CoA contributes to 
signaling that supports the expression of these genes. In chapter 4, we determine 
whether the expression of these genes is regulated by acetyl-CoA, through acetylation at 






Figure 1: Quiescent cell versus proliferating cell metabolism. 
 
Benign quiescent cells in our body generally take up nutrients to support ATP production to support 
homeostatic functions. In proliferating cells, such as cancer, metabolism is increased to support 


































Figure 2: A cancerous web 
 
  
Acetyl-CoA promotes growth and proliferation through multiple mechanisms. Outside of mitochondria, 
acetyl-CoA can be generated from citrate by ATP-citrate lyase (ACLY), from acetate by acyl-CoA 
synthetase short chain family member 2 (ACSS2), and from pyruvate by the pyruvate dehydrogenase 
complex (PDC), which was recently reported to translocate from mitochondria into the nucleus. Acetyl-
CoA has long been known to support growth and proliferation through its roles in the synthesis of fatty 
acids and cholesterol. Acetyl-CoA also participates in the regulation of histone acetylation and gene 
expression, is required for acetylation of numerous metabolic enzymes, and suppresses autophagy. 
Although many details remain to be elucidated, it is clear that acetylation plays crucial roles in 



























Figure 3: Akt promotes acetyl-CoA production 
 
 
Akt promotes glucose uptake which can lead to increased production of acetyl-CoA via 
phosphorylation of ACLY. Acetyl-CoA is important for lipid synthesis and protein acetylation 



















CHAPTER 2:  
MATERIALS AND METHODS 
2.1 Reagents and Cell Lines 
All cell lines used in this study were regularly checked for mycoplasma and authenticated 
using STR profiling. LN229 cells were normally cultured in RPMI with 10% CS (Hyclone) 
and supplemented with 1% L-glutamine (GIBCO). LN229-myrAkt cells have been 
previously described (Elstrom et al., 2004a).  LN229-myrAkt and SF188-myrAkt cells 
were a gift of C.B. Thompson, MSKCC.    LN229-ACLY, -S455A, and –S455D and empty 
vector stable cell lines were generated by transfecting cells with pEF6, pEF6-ACLY(Wild 
Type), pEF6-ACLY(S455A), or pEF6-ACLY(S455D) constructs and selecting. U251 cells 
were normally cultured in DMEM (GIBCO) with 10% heat-inactivated FBS (Gemini Bio-
products) and supplemented with 1% L-glutamine (GIBCO). For experiments, cells were 
grown in glucose free media, supplemented with 10% dialyzed FBS (GIBCO) and 
indicated amounts of glucose and acetate.  Cells were cultured at 37 °C and 5% CO2.  
2.2 Antibodies 
Tubulin (Sigma), NFAT1 (Cell Signaling, Abcam), HA (Thermo-Scientific), H3K27ac 
(Abcam), H4K12ac (Millipore), AcH3, AcH4, H3, H4 (from Millipore), pAktSer473, Akt, 
pACLY-Ser455, pERK, ERK, pS6, S6 (Cell Signaling), ACLY (previously described 
(Wellen et al., 2009)). Antibodies used for IHC on murine tissues: AcH4 (1:2000; clone 
06-759-MN, Millipore), AcH3 (1:500; clone 06-599, Millipore), H3K4me1 (1:2000; 




AbCam) pACLY (1:100; #SAB4504020, Sigma), and pAkt (1:100; clone 736E11, Cell 
Signaling).  
2.3 Expression vectors 
NFAT1 shRNA was in a plko.1 backbone with the following sense sequences- #47: 5’-
GTGAACTTCTACGTCATCAAT -3’, Sho: 5’- CTGATGAGCGGATCCTTAA -3’ previously 
published (Shoshan et al., 2016).  ACLY shRNA #12 and #13 were previously published 
(Sivanand et al., 2017, Lee et al., 2014). ACLY-targeting siRNA pools were obtained from 
Dharmacon and transfected with RNAimax reagent, according to manufacturer’s 
instruction. shRNA for stable silencing of murine Acly [previously described 
(Hatzivassiliou et al., 2005)] HA-tagged NFAT1 constructs were purchased from 
Addgene (CA-NFAT1: Plasmid #11792; WT-NFAT1: Plasmid #11791) and subcloned into 
pLX303 by Gateway Cloning kit (Invitrogen).   
Lentivirus was produced by transfecting 293T cells with the indicated expression 
plasmid, pMD2.G and psPAX2 plasmids using Lipofectamine 2000 (Invitrogen). Virus 
was harvested 48 hours and 72 hours after transfection. For viral infection, cells were 
incubated with medium containing virus and 8µg/ml polybrene for 16 hours. Cells were 
allowed to recover for 24 hours before antibiotic selection, and surviving pools were 





ACLY inhibitor (BMS303141) was dissolved in ethanol. C646 (p300i) was dissolved in 
DMSO. Akt inhibitor VIII (Calbiochem), LY294002 (Cayman Chemical), PD325901 (LC 
Laboratories), rapamycin (50 nM). 
2.5 Preparation of whole cell protein lysate 
Nuclear and cytoplasmic fractionation protocol was followed as previously published 
(Sivanand et al., 2017). Whole cell lysate was prepared with RIPA buffer or direct lysis 
with 2X LDS (Invitrogen). All buffers were supplemented with protease inhibitor cocktail 
(Sigma) and phosphatase inhibitor tablets (Roche).  
2.6 Acid extraction of histones 
Adherent cells were cultured to 80% confluency in 6-well plates and nuclei were 
harvested by gentle lifting in cold NIB buffer (15mM Tris-HCL pH7.5, 60mM KCl, 15mM 
NaCl, 5mM MgCl2, 1mM CaCl2, 250mM sucrose, freshly added: 1mM DTT, 1X protease 
inhibitors, 10mM sodium butyrate, 0.1% NP-40). Nuclei were pelleted at 600 rcf for 5 
min at 4 °C and washed twice using NIB buffer without NP-40. The pellets were 
immediately resuspended in 0.4N H2SO4 and rotated for at least 30 minutes at 4 °C in. 
After centrifugation at 11,000 rcf for 10 min at 4 °C, histones were precipitated from the 
supernatant by addition of 20% tricholoracetic acid (TCA) for at least 1 hour, followed by 
centrifugation at 16,000 rcf for 10 min at 4 °C. The pellet (or white film) was washed 
once with acetone containing 0.1% HCl, and finally with 100% acetone. Histone proteins 





RNA isolated with Trizol was quantified and 1-2ug was used for cDNA synthesis using a 
reverse transcriptase kit (Invitrogen). qPCR was completed with Power SYBR 
(Invitrogen) on ViiA 7 (Applied Biosystems) for a total of 40 cycles. Results were 
analyzed using 𝛥𝛥Ct.  List of primers can be found in the Appendix as Table 1.  
2.8 Chromatin Immunoprecipitation (ChIP) 
Cells were grown to 80% confluency on 10 cm2 dishes on day of harvest and were fixed 
on the dish with 1% formaldehyde for 10 minutes at room temperature. The reactions 
were quenched with 0.125 M glycine. The cells were then washed twice with 1X PB and 
scraped in cell lysis buffer (10 mM Tris-HCl pH8.1, 10 mM NaCl, 1.5 mM MgCl2, 0.5% 
NP-40), supplemented with protease inhibitors (Roche). The cell lysate was then 
incubated for 15 minutes on ice and crude nuclear extracts were collected by 
centrifugation at 600 rcf for 5 min at 4 °C. The pellet was resuspended in 0.5 mL of 
nuclear lysis buffer (50 mM Tris-HCl pH 8.1, 5 mM EDTA, 1% SDS) supplemented with 
protease inhibitors. The chromatin was fragmented with a Diagenode Bioruptor 300 (60 
cycles of 30 sec on followed by 30 sec off, at 4 °C). To remove insoluble components, the 
samples were centrifuged at 13,000 rcf for 15 min at 4 °C and the supernatant were 
recovered. The supernatants were diluted 1:1 with dilution buffer (16.7 mM Tris-HCl pH 
8.1, 1.1% Triton X-100, 0.01% SDS, 167 mM NaCl, 1.2 mM EDTA) supplemented with 
protease inhibitors and quantified by BCA. For each sample, 15 uL of protein G magnetic 
beads (Millipore 16-662) was added to 100 ug of protein in 500 uL of dilution buffer and 




day, samples were washed with each of the following buffers, once, in the order of: low 
salt (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris HCl pH 8.1, 150 mM NaCl), 
high salt (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris HCl pH 8.1, 500 mM 
NaCl), LiCl (1% NP-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH 8.1, 250 mM 
LiCl), and TE (10mM Tris-HCl pH 8.1, 1 mM EDTA). ChIP DNA was eluted off the beads 
by incubating beads in 125 uL elution buffer (10 mM Tris-HCl pH 8.1, 1 mM EDTA, 1% 
SDS, 150 mM NaCl), supplemented with DTT to a final concentration of 5 mM, for 10 
minutes at 65 °C. The supernatant was removed and ChIP DNA was eluted a second time 
in the same fashion. The combined supernatant was then incubated overnight at 65 °C to 
reverse crosslinks and proteinase K treated for 1 hour the next morning. Samples were 
purified using Macherey-Nagel DNA purification kit, with NTB binding buffer (for 
purification of DNA in high SDS). 
ChIP samples were diluted 1:20 in water and used as template in the Power Sybr 
Master Mix (Invitrogen) and DNA was amplified using the ViiA-7 Real-Time PCR 
system. Results were calculated as percent input. All primers were designed for the 
human gene at -1 kb upstream of the TSS, unless otherwise indicated. For primer set, the 
sequence from 5’ -> 3’ are: SERPINA5 - Forward: GGATATCCAACAGCCACATAATTG; 
Reverse: GTTCAGCAAACACTGTCCATC. PDGFRA - Forward: 
GGGAGAAGGATGAAGGATGAC; Reverse: GATGCTCCAGGAACCAGAC. E2F2 - 
Forward: GGAGAATCACTTTAACCCAGGA; Reverse: GTCTGAGGCAAGGTCTCTTT. 





2.9 YSI metabolite and doubling time measurements 
Glucose and glutamine consumption and lactate production were measured using 
a YSI 7100 Bioanalyzer.  Measurements were conducted over a 24-hour time period and 
normalized to cell number area under the curve, as previously described (Londono 
Gentile et al., 2013, Jain et al., 2012).  Briefly, metabolite consumption was defined as v 
= V(xmedium control -  xfinal)/A, where v is metabolite consumption/production, V is culture 
volume, x is metabolite concentration, and A is cell number area under the curve.  A was 
calculated as N(T)d/ ln2(1-2-T/d), where N(T) is the final cell count, d is doubling time, 
and T is time of experiment.  Doubling time was calculated as d = 
(T)[log(2)/log(Q2/Q1)], where Q1 is starting cell number and Q2 is final cell number, as 
determined by manual counting using a hemocytometer.  
2.10 Mass spectrometry analysis of histones 
For 12C study, LN229 cells in triplicate wells were incubated for 24 hours in 1 mM 
or 10 mM glucose.  For 13C study, LN229 cells were first cultured in 1 mM glucose 
overnight.  Triplicate wells of cells were then treated with 1 or 10 mM [U-13C]-glucose for 
2 or 24 hours.  Histones were acid, as described above. Total histones were subjected to 
chemical derivatization using propionic anhydride (Sigma-Aldrich) and digested with 
sequencing grade trypsin at a 10:1 substrate to enzyme ratio for 6 hours at 37°C.  The 
digested peptides were treated with an additional round of propionylation for the 
purpose of adding propionyl group to the newly generated N-terminus. Peptides were 
desalted using C18 extracted mini disk (Empore 3M, MN, USA) and dissolved in 0.1% 




nLC, Thermo Fisher Scientific Inc) onto a homemade 75µm reversed phase analytical 
column packed with 15cm C18-AQ resin (3µm particle sizes, 120 Å pore size) at a rate of 
550nl/min. Peptides were chromatographically resolved on a 66-min 2-98% solvent B 
gradient (solvent A = 0.1% formic acid, solvent B = 100% acetonitrile) at a flow rate of 
250 nL/min. The eluted peptides were electrosprayed through a PicoTip emitter (New 
Objective Inc, Woburn, MA) into and detected by LTQ Orbitrap Velos mass spectrometer 
(Thermo Fisher Scientific Inc) with a resolution of 60,000 for full MS spectrum followed 
by MS/MS spectra obtained in the ion trap.  
After the MS data were generated, an in-house program was developed to 
calculate the relative intensity of 13C enriched acetyl groups. For example, there are four 
acetyl groups in H4 4-17 4ac, with 2-Dalton mass shift between adjacent groups. Because 
the isotope patterns of adjacent groups overlap, the intensity from the former group 
should be subtracted. After calibration, the intensity of each group divided by the total 
intensity is the relative intensity. 
2.11 RNA-sequencing 
LN229 cells were incubated for 24 hours in 1 mM or 10 mM glucose, or 1 mM 
glucose + 5 mM sodium acetate.  RNA was isolated using Trizol reagent and submitted to 
the Functional Genomics Core at the University of Pennsylvania for library preparation 
and sequencing.  Details of data analysis and clustering may be found in the supplement.  




2.12 LC-MS metabolite measurements 
Acetyl-CoA and CoASH measurements were conducted as previously described 
(Basu and Blair, 2012, Basu et al., 2011). For molar concentrations, measurements were 
normalized to cell volume, as determined using a Coulter Z2 particle counter.  Protocol 
for citrate and glutamate analysis followed a 90:10 Methanol:water extraction and is also 
described in (Lee et al., 2014).  
Metabolomics: PEP and Citrate: Cells were grown on 6 well dish format. After 
treatment with 1 mM glucose overnight, glucose and/or acetate was added to the media 
for indicated amount of time. At harvest, aspirate media off cells and scrape directly into 
1 ml super cold 80:20 MetOH:water. Samples were transferred to 1.5 ml tube.  Standards 
for PEP were added to 1 ml MetOH:water. Internal standard (20 uL of U-13C-Citrate 0.05 
ug/ul) was added to every sample and standard. Samples were centrifuged 17,000 rcf 4 C 
10 min and the supernatant was transferred to glass tubes for drying under nitrogen. 
Pellets were resuspended in 100 ul of water and mass analysis was determined on TSQ 
instrument. 
2.13 Histone acetylation in isolated nuclei assay 
Nuclei were isolated from approximately 9 x 106 adherent LN229 cells by using a 
cell lifter and cold NIB buffer (15mM Tris-HCL pH7.5, 60mM KCl, 15mM NaCl, 5mM 
MgCl2, 1mM CaCl2, 250mM sucrose, 0.1% NP-40). Nuclei were pelleted at 600 rcf for 5 
min in 4°C and followed by two washes using NIB buffer without NP-40. Nuclei were 




without NP-40 for 1 hour at 37°C. After incubation, nuclei were pelleted at 600 rcf for 5 
min and subject to acid extraction (described in Supplement).  
2.14 Immunohistochemistry and scoring of murine tissues 
For histological evaluation, tissue samples were harvested as described (Gunther 
et al., 2002, Rhim et al., 2012). Immunohistochemistry was performed on paraffin-
embedded sections. Tissue sections were dewaxed and rehydrated. Antigen retrieval was 
performed by boiling samples in Citrate Buffer pH6 for 20 min (for AcH4, AcH3 and 
H3K4me) or in Tris-EDTA 10mM Buffer pH9 for 45 min (pACL), and endogenous 
peroxidase was blunted by incubating samples with 3% H2O2 for 10 min. After 
incubation with the primary antibody, slides were rinsed in PBS and signals were 
developed using the Vectastain Elite Kit and 3,3′-diaminobenzidine as a substrate for the 
peroxidase chromogenic reaction (Vector Laboratories, Burlingame, CA).  At least 3 
animals/group were evaluated. All animal studies were approved by the University of 
Pennsylvania Institutional Animal Care and Use Committee (IACUC). 
Quantification of AcH4 positivity in acinar cells in Kras WT and KPCY mice 
(n=5/ group) was performed in a semi-automated manner using ImageJ software. For 
each animal, 5 to 10 images from different, non-overlapping microscopic fields were 
analyzed. Images containing malignant or pre-malignant lesions were excluded from the 
analysis. Count of nuclei within each image was calculated using ImageJ while positive 





2.15 Immunohistochemistry and automated scoring for human gliomas 
Cases were obtained from the University of Pennsylvania following approval from 
the institutional review board. All cases were de-identified prior to analysis and were 
contained in a previously well-characterized tissue microarray sections (Venneti et al., 
2013a). The cohort consisted of a total of 56 glioma samples (4 WHO grade II 
oligodendrogliomas, 5 grade III anaplastic oligodendrogliomas, 6 grade II 
oligoastrocytomas, 4 grade I pilocytic astrocytomas, 4 grade II diffuse astrocytomas, 9 
grade III anaplastic astrocytomas, 14 grade IV glioblastomas, 2 grade I gangliogliomas 
and 8 grade II ependymomas). A neuropathologist evaluated all cases.  
Immunohistochemical studies and quantification were performed as previously 
described (Venneti et al., 2013b). Details may be found in Supplement.   
2.16 Immunohistochemistry and scoring of human prostate tumors 
Cases were obtained from the University of Pennsylvania following institutional 
review board approval.  TMAs were assembled from primary tumors from 49 patients 
with either metastatic (n=25) or localized (n=24) disease.  5 µm sections from formalin-
fixed paraffin-embedded (FFPE) TMA (Tissue Microarray) tissue blocks were prepared 
for immunohistochemical stain. Details of staining and scoring provided in Supplement.   
2.17 Transwell Migration Assay 
Transwell migration assays were completed on 8 𝜇m pore membranes in 6-well format 
(Corning). Cells were pretreated with 1 mM glucose and 250,000 cells were seeded with 




lower chamber as a chemoattractant. After 24 hours, cells that did not migrate were 
cleaned off the top of the membrane with a cotton swab, and migrated cells were fixed, 
then stained with DAPI. Quantification was done with ImageJ using the automated cell 
counting feature. 
2.18 Scratch Assay 
Cells were grown in a monolayer to 80% confluency and then scratched with a p200 
pipet tip on a 6-well plate (Sarstedt) and incubated overnight with indicated media 
conditions. Cell positions were recorded on Leica microscope for accurate 
measurements. Area of wound was quantified with ImageJ.  
2.19 Brain ECM Adhesion Assay 
LN229 glioblastoma cells were pretreated as described above. Cells were then 
trypsinized and reseeded for adhesion experiments on coverslips prepared as previously 
described (Barney et al., 2015) with brain-inspired ECM proteins: 50% fibronectin (EMD 
Millipore), 25% vitronectin (R&D Systems), 20% tenascin C (R&D Systems), and 5% 
laminin (Life Technologies) (all weight%). Briefly, glass coverslips were UV ozone-
treated for 10 minutes (Bioforce Nanoscience), and functionalized through sequential 
deposition of (3-Aminopropyl)triethoxysilane (Sigma), N,N-disuccinimidyl carbonate 
(Sigma) and diisopropylethylamine (Sigma), then ECM proteins. For adhesion 
experiments, cells were seeded at 4000 cells/cm2 in low glucose medium and imaged 10 
minutes after seeding, in 5 minute intervals, for 2h using a Zeiss Axio Observer Z1 
microscope (Carl Zeiss). ImageJ (National Institutes of Health) was used to manually 




2.20 Statistical Analyses 
Unless otherwise indicated, Student’s 2-tailed t-tests were used for all analyses 
directly comparing 2 datasets.  For in vitro assay testing AcCoA and CoASH effects on 
histone acetylation, repeated measures one-way ANOVA was used, with posttest for 
linear trend.  For correlations shown for human IHC, Pearson’s product-moment 
correlation coefficient (Pearson’s r) and corresponding 2-tailed significance (p value) 
was determined.    
2.21 Calcium Imaging 
LN229 cells stably expressing (G418 selected) pGP-CMV-GCaMP6f (Chen et al., 
2013a) were adhered to X and Y coated coverslips and maintained in culture medium 
(RPMI, 10% dFBS, supplemented with L-glutamine) in a temperature and CO2 
controlled chamber mounted on the stage of a fluorescence microscope and GCaMP6f 
images of individual cells were captured every 15 seconds for 1 hour following addition of 
medium containing 1 mM glucose, 1 mM glucose with 5 mM acetate, or 10 mM glucose. 
2.22 Immunofluorescent detection of NFAT1 
Cells were grown on 22 mm glass coverslips in a 6 well dish. Cells were fixed with 3% 
formaldehyde in 1X PBS for 10 minutes at room temperature. Each well was washed 2X 
with 1X PBS to remove traces of formaldehyde then permeablized for 5 minutes on ice 
with 0.1% Triton in PBS (PBS-T). The following steps were all performed at room 
temperature. Coverslips were blocked with 3% nonfat milk in PBS-T (filtered) for 15 




minutes. After incubation, coverslips were washed 3X with PBS-T for 1 minute and 
incubated with secondary antibody diluted in 3% milk in PBS-T at 1:1250 for 30 minutes, 
protected from light. Coverslips were washed 3X with PBS-T for 1 minute, stained with 
Hoechst, and then washed 2X with PBS-T, and mounted. Photos were taken on Olympus 
inverted microscope. Quantification of percent nuclear was completed by counting in a 
blinded to treatment conditions.  
2.23 Animals  
Xenograft tumor experiments were approved by the Animal Care and Use Committee at 
the University of Pennsylvania. Briefly, seven female athymic nude mice (Charles River, 
7 weeks old) were injected subcutaneously with 1.5 million of vector control LN229 cells 
or sg3.8 cells in the left or right flank, respectively. Before each injection, cells were 
resuspended in 200 µL DMEM mixed with an equal volume of matrigel (BD Bioscience). 
Once palpable tumors were established, tumors size was measured twice a week with a 
digital caliper. After 6 weeks mice were sacrificed by CO2 euthanasia, and xenograft 
tumors were dissected, weighed, and snap frozen with liquid nitrogen until further 
analysis.  
2.24 Transcription factor identification  
The upregulated subset of genes from the 881 acetyl-CoA regulated genes (Lee et al., 
2014) were entered into the Broad Institute’s Molecular Signatures Database (MSigDB) 
v4.0 with FDR q-value set to below 0.05. Top 10 transcription factor targets (TFT) was 




enrichment of TGGAAA_V$NFAT_Q4_01 using GSEA v3.0 with 1000 permutations and 




CHAPTER 3:  
AKT-DEPENDENT METABOLIC REPROGRAMMING REGULATES TUMOR CELL 
HISTONE ACETYLATION 
 
Chapter 3 is based on and mostly a reprint of the paper: Lee, J. V., Carrer, A., Shah, S., 
Snyder, N. W., Wei, S., Venneti, S., et al. (2014). Akt-Dependent Metabolic 
Reprogramming Regulates Tumor Cell Histone Acetylation. Cell Metabolism, 20(2), 
306–319. 
3.1  Introduction 
Rewiring of cellular metabolism in cancer cells is crucial for increased 
macromolecular biosynthesis, growth, and proliferation, and metabolic deregulation is 
now considered a hallmark feature of cancer cells (Hanahan and Weinberg, 2011, Ward 
and Thompson, 2012).  In addition to directly supporting energetics and biosynthesis, a 
growing body of evidence suggests that metabolic enzymes may also promote 
tumorigenesis through functions that are not overtly metabolic.   For example, the M2 
isoform of pyruvate kinase, a glycolytic enzyme, has been reported to enter the nucleus 
and serve as transcriptional coregulator (Luo and Semenza, 2012). ATP-citrate lyase 
(ACLY), a lipogenic enzyme, is also present in the nucleus and plays a crucial role in 
regulating nuclear acetylation events, including histone acetylation (Wellen et al., 2009).  
Metabolic changes in cancer cells are typically mediated by activation of 
oncogenes and/or loss of tumor suppressors (Metallo and Vander Heiden, 2010, Vander 




alterations.  In addition to genetic mutations, epigenetic alterations play a key role in 
enabling malignant transformation and tumor growth (Shen and Laird, 2013, Azad et al., 
2013), although mechanisms underlying epigenetic alterations in cancer are not fully 
clear. Notably, many chromatin-modifying enzymes depend on metabolic intermediates 
as cofactors or substrates and certain chromatin modifications have been shown to be 
sensitive to the cellular metabolic state [reviewed in (Katada et al., 2012, Kaelin and 
McKnight, 2013, Lu and Thompson, 2012a, Yun et al., 2012)].   Links between cancer cell 
metabolism and DNA and histone methylation have been recently identified in tumors 
with specific mutations, such as those in isocitrate dehydrogenase (IDH1 and IDH2).  
Mutant IDH enzymes exhibit altered enzyme activity favoring conversion of a-
ketoglutarate (aKG) into (R)-2-hydroxyglutarate, a metabolite that inhibits the activity 
of aKG-dependent JmjC-domain histone demethylases and TET enzymes, resulting in 
hypermethylation of DNA and histones [reviewed in (Ward and Thompson, 2012, 
Losman and Kaelin, 2013)].  Succinate dehydrogenase (SDH) mutations and 
nicotinamide N-methyltransferase (NNMT) overexpression also result in methylation 
changes in cancer cells (Ulanovskaya et al., 2013, Killian et al., 2013, Letouze et al., 2013, 
Xiao et al., 2012).  In these specific cases, the epigenetic alterations are a direct result of 
altered activity of a particular metabolic enzyme.  However, it is not known whether 
metabolism might more universally contribute to tumor epigenetic deregulation.  
Histone acetylation is a dynamic chromatin mark, with important roles in gene 
regulation, DNA damage repair, and DNA replication.  Global histone acetylation has 
also been implicated in contributing to pH balance and postulated to serve as a depot for 




McBrian et al., 2013).  The metabolite acetyl-coenzyme A (acetyl-CoA) is the required 
donor substrate used by lysine acetyltransferase (KAT) enzymes.  In cells cultured under 
standard conditions, glucose-derived carbon supplies the majority of acetyl-CoA used for 
histone acetylation, although glutamine and acetate also contribute (Evertts et al., 2013).  
In some conditions, fatty acid breakdown can also contribute to nuclear acetyl-CoA and 
histone acetylation (Donohoe et al., 2012).  Acetyl-CoA is compartmentalized into 
mitochondrial and nuclear-cytoplasmic pools (Takahashi et al., 2006).  Production of 
nuclear-cytoplasmic acetyl-CoA from glucose, glutamine, or fatty acids depends on 
export of citrate from the mitochondria, where it is cleaved by ACLY to generate acetyl-
CoA and oxaloacetate.  Acetate also supplies nuclear-cytoplasmic acetyl-CoA through 
acetyl-CoA synthetase (AceCS1/ ACSS2).  Together, ACLY and AceCS1 are the primary 
enzymatic sources of acetyl-CoA outside of the mitochondria.  Several studies have 
demonstrated that histone acetylation levels are highly sensitive to the availability of 
acetyl-CoA, in cell types from yeast to human (Cai et al., 2011, Takahashi et al., 2006, 
Wellen et al., 2009). 
Given that production and utilization of metabolites is dramatically altered in 
cancer cells, and that histone acetylation is responsive to acetyl-CoA availability, we 
postulated that metabolic reprogramming in tumor cells might alter acetyl-CoA and 
histone acetylation levels in tumors.  In this study, we provide evidence that metabolic 
reprogramming orchestrated by oncogenic activation of Akt drives changes in acetyl-CoA 
production and histone acetylation that are reflected in total histone acetylation levels in 
tumors. To our knowledge, this study is the first demonstration that metabolic 
reprogramming mediated by oncogenic activation of a signal transduction pathway plays 





3.2.1 Histone acetylation is variably sensitive to glucose in cancer cells 
We previously showed that ACLY plays a key role in determining global histone 
acetylation levels in cancer cells.  Histone acetylation is markedly reduced upon silencing 
of ACLY and can be restored by supplementing cells with the alternate acetyl-CoA source 
acetate, indicating that the ability of cells to produce acetyl-CoA can limit histone 
acetylation (Wellen et al., 2009).  To determine whether glucose availability regulates 
histone acetylation levels in cancer cells, we examined a panel of cancer cell lines, 
including glioblastoma, prostate cancer, and breast cancer cell lines.  Histone acetylation 
was sensitive to glucose availability in each of the cell lines examined, to varying degrees 
(Figure 4A and Figure 5A).  As we have previously shown in other cell types (Wellen 
et al., 2009), silencing of ACLY inhibited glucose-dependent histone acetylation in 
LN229 cells (Figure 5B).   
In LN229 glioblastoma cells, proliferation slowed when cultured in 1 mM glucose, 
but between 2 and 25 mM glucose doubling time was equal, indicating that histone 
acetylation patterns are regulated by glucose independently of cell proliferation (Figure 
5C).  Cells remained viable in all conditions (Figure 5C). As glucose was progressively 
limited, glutamine consumption increased (Figure 5C).  Although glutamine can be 
used to supply nuclear-cytoplasmic acetyl-CoA, LN229 cells failed to sustain high histone 
acetylation levels in low glucose despite increased consumption of glutamine (Figure 




We next sought to define which histone lysines are most sensitive to glucose 
availability. LN229 cells were incubated for 24 hours in 1 mM or 10 mM glucose and 
histone modifications analyzed by mass spectrometry.  Higher acetylation in 10 mM than 
1 mM glucose was observed at all H2A, H3, and H4 tail lysines analyzed (Figure 5D). To 
confirm that this is due to reduced glucose carbon incorporation into acetylated histones, 
this analysis was repeated in 1 mM or 10 mM [U-13C6]-glucose. After 24 hours, 
enrichment was reduced in low glucose for all lysines analyzed.  However, the effects of 
glucose limitation became more pronounced as more lysines were acetylated in cis.  For 
example, the histone H4 tail can be acetylated at lysines 5, 8, 12, and 16.  In 1 mM [U-
13C6]-glucose, significantly more tetra-acetylated histone H4 (AcH4) tails were enriched 
at 0 or 1 acetyl group, while in 10 mM, 3 or 4 acetyl groups were more frequently 
enriched (Figure 5E).  Thus, these data indicate 1) that on all tail lysines examined, 
acetylation is sensitive to glucose availability and 2) that glucose limitation has a greater 
impact on histone tails with multiple lysines acetylated in cis. 
Supplementation of acetate restored histone acetylation levels in low glucose 
conditions (Figure 4B).  Correspondingly, acetyl-CoA levels were reduced in low 
glucose conditions and significantly rescued by addition of acetate (Figure 4C).  To 
determine whether specific gene sets correlated with these effects on histone acetylation, 
we performed RNA-sequencing to identify acetyl-CoA regulated genes (genes suppressed 
or induced by low glucose and reversed by acetate). Approximately 10% of glucose-
regulated genes were also significantly regulated by acetate (Figure 4D).  Clustering 
analysis revealed that acetate regulated most genes in the same direction as glucose, 
suggesting that acetyl-CoA is a key mediator of glucose-dependent gene expression 




(Figure 7A), and ChIP analyses at these genes showed that promoter histone 
acetylation correlated with expression (Figure 7B). Analysis of curated pathways 
revealed enrichment for genes involved in cell cycle and DNA replication among acetyl-
CoA-induced genes, suggesting that acetyl-CoA stimulates a pro-proliferative gene 
expression profile (Figure 4F).  Analogously, prior studies in yeast showed that acetyl-
CoA promotes cell growth and division by promoting expression of genes involved in 
these processes (Cai et al., 2011). Although acetate supplementation was not sufficient to 
restore normal doubling time in low glucose conditions in LN229 cells (Figure 4G), we 
considered that additional glucose-derived components might be required.  Indeed, 
supplementation of acetate together with nucleosides (synthesis of which requires ribose 
generated in the pentose phosphate pathway), rescued doubling time, while neither 
component alone did so (Figure 4G). These data suggest that acetyl-CoA facilitates 
expression of proliferation-related genes, as part of an integrated growth response. 
3.2.2 Acetyl-CoA and Coenzyme A are key determinants of histone acetylation in 
cancer cells 
If acetyl-CoA serves as a signal of nutrient sufficiency to promote growth and 
proliferation, cells must have mechanisms to detect changes in acetyl-CoA abundance.  
Work in yeast has shown that Gcn5 is crucial for mediating histone acetylation in 
response to acetyl-CoA availability (Cai et al., 2011, Friis et al., 2009).   In yeast, acetyl-
CoA concentrations oscillate within a range that could plausibly regulate yeast Gcn5, 
which has a Kd of 8.5 µM (Cai et al., 2011).  However, human GCN5 binds acetyl-CoA 
much more tightly (Kd of 0.56 µM) (Langer et al., 2002).  This suggests either that levels 




acetyl-CoA is not the key regulatory factor for overall histone acetylation levels in human 
cells.  Of note, many HATs including GCN5 are inhibited by the product coenzyme A 
(CoA) and bind acetyl-CoA and CoA with similar affinities.  Hence, it has been postulated 
that the ratios of these metabolites might be the critical determinant for overall histone 
acetylation levels (Albaugh et al., 2011).  
We therefore measured absolute acetyl-CoA and CoASH (reduced CoA) 
concentrations, normalizing to cell volume, in LN229 cells cultured in 1 or 10 mM 
glucose.  Acetyl-CoA was measured at 6-13 µM in high glucose conditions and fell to 2-3 
µM in low glucose. CoASH tended to rise in low glucose, and the ratio of acetyl-CoA: 
CoASH was found to be ~1.5- 2 throughout the time course in high glucose conditions 
and to fall below 1 under low glucose (Figure 6A).  We also examined acetyl-CoA and 
CoASH levels in a second cell line, IL-3-dependent hematopoietic cells, since the volume 
of these cells under standard conditions and during nutrient and growth factor 
withdrawal has been extensively characterized (Wellen et al., 2010)  A similar range of 
acetyl-CoA concentrations (~3-12 µM) were measured in these cells as in LN229 cells, 
and both acetyl-CoA and acetyl-CoA: CoASH were significantly reduced when cells were 
deprived of either glucose or growth factor (Figure 6B).  The range of acetyl-CoA 
concentrations observed in each of these cell lines is comparable to that reported over 
the yeast metabolic cycle (Cai et al., 2011).  
To specifically test whether histone acetylation levels respond to both acetyl-CoA 
and CoA levels, nuclei were isolated from LN229 cells and incubated with defined 
concentrations of acetyl-CoA and CoASH, which can freely enter the nucleus through the 




CoASH suppressed histone acetylation in a dose-dependent manner (Figure 6C). 
Together, these data indicate that levels of both acetyl-CoA and CoA in the nucleus can 
impact histone acetylation levels.  Moreover, the ratio of acetyl-CoA: CoASH is glucose-





Figure 4: Glucose Availability Regulates Histone Acetylation in Several 
Cancer Cell Lines  
(A) Acetylation of acid-extracted histones from cells cultured under indicated glucose 
conditions for 24 hours. Total histones were stained by Coomassie or Ponceau. (B) 
Acetylation of acid extracted histones from LN229 cells treated with 1 or 10 mM glucose, +/− 5 
mM NaOAc for 24 hours (C) Relative levels of acetyl-CoA in LN229 cells after 24 hours of 
indicated treatment, mean +/− SEM of triplicates (*, p<0.05; **, p<0.005) (D) Venn diagram of 
genes regulated by glucose and/or acetate in LN229 cells, with the overlap representing 
genes designated as acetyl-CoA-regulated (E) Heatmap of 881 genes represented in the 
overlap from the Venn diagram. (F) DAVID functional annotation of pathways regulated by 
acetyl-CoA, using the gene list identified from the indicated clusters on the heatmap. (G) 
Doubling time for LN229 cells treated as indicated for 24 hours, mean +/− SEM of triplicates 


























































































Enriched acetyl groups 
AcH4(K5/8/12/16) 
24 hr: 10 mM 13C-glc 








Glucose (mM) 1 10 1 10 1 10 






H4 4-17 (K5/8/12/16) 




































shACL  shCtrl 




Glucose availability regulates histone acetylation in cancer cells. (A) Western blot analysis of 
histones acetylation in cancer cell lines cultured under indicated glucose conditions for 24 hours. 
Total acid-extracted histones were stained by Coomassie or Ponceau. (B) LN229 cells were 
transfected with Ctrl or ACLY-targeting siRNA (left panel) or transduced with Ctrl or ACLY-targeting 
shRNA (right panel). Cells were starved in 1 mM glucose, then treated with 1 mM or 10 mM glucose 
for 24 hours. Western blot analysis of acid extracted histones and other signaling components in 
whole cell lysates. (C) Viability, doubling time, and glutamine consumption were measured in LN229 
cells after 24 hours of growth under indicated glucose concentrations, mean +/- SEM of triplicates (*, 
p<0.05; ***, p<0.0005). (D) Indicated histone tail peptides were analyzed by mass spectrometry. Fold 
change in acetylation between 10 mM: 1 mM glucose is graphed, mean +/- SEM of 10 mM sample 
triplicates over average 1 mM value. See Table S1 for complete data set. (E) MS analysis of acid 
extracted histone proteins from LN229 cells incubated with [U-13C6]- glucose for 24 hours. 
Enrichment of tetra-acetylated H4 after 24 hours in 1mM and 10mM [U-13C6]-glucose, mean +/- SD 




Figure 6: Acetyl-CoA:CoASH Ratio Is a Determinant of Histone Acetylation 
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(A) Molar concentrations of acetyl-CoA, CoASH, and ratio of acetyl-CoA: CoASH over 24 hours in 
LN229 cells, mean +/− SEM of triplicates. Result is representative of 3 independent experiments. 
(B) IL-3-dependent bax−/−bak−/− cells were cultured for 48 hours +/− glucose, +/− IL-3 as 
indicated. Acetyl-CoA and CoASH were measured and normalized to cell volume, mean +/− SD of 
triplicates. Significance as compared to Glc+IL-3+ samples (**, p<0.005, ***, p<0.0005) (C) 
Representative Western blot of acetylated histones upon incubation of isolated nuclei with varying 
concentrations of acetyl-CoA and CoASH. Total histones were stained by Ponceau. Data was 
quantified from four independent experiments with 25:0 value set to 1, mean +/− SEM. Repeated 
measures one-way ANOVA with post test for linear trend was performed for 25:10–25:100 values. 
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A) QPCR validation of select genes identified by RNA-Seq as glucose- and acetate-regulated, mean +/- 
SEM of triplicates (*, p<0.05; **, p<0.005; ***, p<0.0005) (B) AcH4 ChIP at promoter of each of genes in 





3.2.3 Expression of KrasG12D in the mouse pancreas promotes increases histone 
acetylation prior to tumor development 
Since histone acetylation is sensitive to metabolic state and metabolism is altered 
in cancer cells, we next asked whether oncogene activation could drive changes in 
histone acetylation in vivo.  Oncogenic Kras mutations are found in the vast majority of 
human pancreatic adenocarcinoma (PDA) cases, and recent studies have demonstrated 
that mutant Kras in pancreatic cancer cells drives extensive metabolic rewiring (Ying et 
al., 2012, Son et al., 2013).  We observed that in the pancreas of healthy wt mice, acinar 
cells exhibited very low levels of AcH3 and AcH4, as detected by immunohistochemistry 
(IHC), although ductal cells were strongly positive for these marks (Figure 8A).  In 
contrast, in mice expressing oncogenic Kras [LSL-KrasG12D; p53L/+; Pdx1-Cre (KPC) 
mice], areas of acinar-to-ductal metaplasia (ADM), precancerous pancreatic 
intraepithelial neoplasia (PanIN), and PDA exhibited high levels of AcH3 and AcH4 
(Figure 8 A, B). PDA may arise from acinar cells (Morris et al., 2010), and strikingly, 
elevated AcH4 was observed in acinar cells even prior to increases in proliferation, as 
assessed by Ki67 immunostaining (Figure 8C), or the appearance of any histological 
abnormalities (Figure 9A, B).  Thus histone acetylation levels are elevated upon 
KrasG12D expression in mouse pancreas early in the process of tumor development.   
We next interrogated signaling pathways downstream of Kras to identify those 
responsible for elevating histone acetylation in primary murine PanIN cells.  Reductions 
in histone acetylation were observed with each of the inhibitors that we tested (Figure 
10A).  PI3K and Akt inhibition also significantly reduced glucose uptake and lactate 




at Ser455 has been shown to increase ACLY’s activity (Potapova et al., 2000).  On the 
other hand, the level of AceCS1, which produces nuclear-cytoplasmic acetyl-CoA from 
acetate, was somewhat suppressed by PI3K, but not by Akt, inhibition in these cells 
(Figure 10A). Acetyl-CoA and acetyl-CoA: CoASH levels were potently suppressed upon 
Akt inhibition (Figure 10C), and histone acetylation levels in Akt inhibitor-treated cells 
increased upon supplementing cells with acetate (Figure 10D).  Suppression of histone 
acetylation by Akt inhibition was comparable to that observed upon either glucose 
limitation or ACL silencing, both of which were also rescued by acetate (Figure 10D).  
In primary murine PDA cells, we similarly observed suppression of histone acetylation 
and glucose uptake by PI3K or Akt inhibition, as well as acetate rescue of histone 
acetylation in Akt inhibitor- or low glucose-treated cells (Figure 11B-D).  These data 
indicate that in premalignant and cancerous cells expressing oncogenic Kras, histone 














































Pancreata from mice expressing Kras-G12D (KPCY) were harvested at either 6 weeks 
(KPCY-Normal Area), 8 weeks (KPCY-PanIN) or 10 weeks (KPCY-PDA) of age, along 
with pancreata from control (Kras WT) mice (n≥3, each group). Immunohistochemistry 
against AcH4 (A), AcH3 (B) or Ki67 (C) was performed on paraffin-embedded tissue 
sections and nuclei were counterstained with hematoxylin. Representative images are 




Figure 9: KrasG12D expression increases histone H4 acetylation in pancreatic 































Mouse: #1 #2 #3 #4 #5 #6 #7 #8 #9 #10
Pancreata from either wild type (Kras WT) or oncogenic Kras (KrasG12D)-expressing 
mice were harvested at 6 weeks of age (n=5, each group). Acinar cell nuclei positive 
for acetylated histone H4 (AcH4) were quantified by immunohistochemistry. The 
scientist who performed the quantitation was blinded to the genotypes of the mice. 
Percentages of AcH4-positive acinar cell nuclei were calculated in different, non-
overlapping microscopic fields and plotted (each dot refers to a different microscopic 





Figure 10: Oncogenic Kras Enhances Histone Acetylation In Vitro in an Akt- 
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(A) Mouse pancreatic primary cells derived from KPCY mouse PanIN lesions were treated 
with indicated inhibitors for 24 hours. Acetylation of histones and phosphorylation of 
signaling proteins were assessed by Western Blot in acid extracts and RIPA lysates, 
respectively. Ponceau staining is shown as loading control for histones. (B) Glucose 
consumption and Lactate production were measured in PanIN-derived primary mouse 
cells treated as in (A), mean +/− SD of triplicates (*, p<0.05). (C) Acetyl-CoA and CoASH 
levels were measured in PanIN cells, +/− Akt inhibitor, mean +/− SD of triplicates (***, 
p<0.001). (D) PanIN-derived primary cells were transduced with control (shCtrl) or ACL-
targeting (shACL) short hairpin RNA. Cells were cultivated under indicated glucose 
concentrations, +/− Akt inhibitor, +/− 5 mM acetate for 24 hours. Histones were acid-






Figure 11: Akt regulates histone acetylation in PanIN and PDA cells 
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(A) PanIN-derived primary cells were transduced with control (shCtrl) or Acly-targeting (shAcly 
#4) short hairpin RNA. Cells were cultivated under indicated glucose concentrations, with or 
without 5 mM acetate for 24 hours. Histones were acid-extracted and analyzed by Western 
Blot. Ponceau staining is shown as loading control for histones. (B) Mouse PDA-lesion derived 
cells from KPCY mice were cultured and either mock-treated (DMSO) or treated with the 
indicated inhibitors for 24 hours. Acetylation of acid-extracted histones was assessed by 
Western Blot. (C) Glucose consumption and Lactate production were measured in PDA-derived 
primary mouse cells treated as in part A, mean +/- SD of triplicates (**, p<0.005; *, p<0.05). (D) 
PDA-derived primary cells were cultured in high (25 mM) or low (4 mM) glucose conditions, with 
or without Akt inhibitor and with or without 5 mM acetate for 24 hours. Histone acetylation levels 





3.2.4 Akt activation sustains histone acetylation in nutrient-limited conditions  
To probe further into the mechanism whereby Akt regulates histone acetylation, 
we examined the effects of constitutive Akt activation in cancer cells by comparing 
parental LN229 cells with LN229 cells in which a constitutively active form of Akt, 
myristoylated Akt (myrAkt), was stably expressed.  LN229-myrAkt cells have been 
shown to consume more glucose but maintain a similar proliferation rate as parental 
cells (Elstrom et al., 2004a).  Levels of histone acetylation in high glucose conditions 
were not markedly different between the two cell lines.  However, when cultured in low 
glucose, LN229-myrAkt cells sustained a significantly higher level of histone acetylation 
than parental cells (Figure 12A).  Similar results were also obtained in SF188 and 
SF188-myrAkt cells (Figure 13A). Time course analysis indicated that myrAkt 
expression extended the timeframe over which cells could maintain histone acetylation 
levels in low glucose (Figure 13B). 
Glucose deprivation results in depletion of ACLY’s substrate citrate in LN229 
cells (Figure 14A).  In myrAkt-expressing cells, citrate levels were lower than in the 
parental cells, even in high glucose conditions, and loss of citrate was accelerated upon 
glucose deprivation (Figure 14A).  In vitro studies of ACLY enzymatic activity have 
demonstrated that phosphorylation at Ser455 increases the enzymatic activity of ACLY, 
resulting in a 6-fold increase in V(max) (Potapova et al., 2000).  Hence, increased 
phosphorylation of ACLY by Akt could potentially enable sustained acetyl-CoA 
production and thereby histone acetylation even if availability of the ACLY substrate 
citrate is reduced.  To test whether ACLY phosphorylation is sufficient to sustain high 




phospho-mimetic (S455D) and phospho-mutant (S455A) proteins in LN229 cells.  
Expression of ACLY-S455D enabled high levels of histone acetylation to be sustained in 
low glucose, similar to that observed with myrAkt expression (Figure 12B).  A trend 
towards higher histone acetylation in low glucose was also noted with expression of WT-
ACLY. These results suggest that ACLY is a key downstream effector of Akt in promoting 
histone acetylation, particularly when nutrients are limited.    
This result raised the question of where cells obtain the carbon for histone 
acetylation in cells with constitutive Akt/ACLY activation but limited glucose.  Recent 
studies have shown that under certain conditions such as hypoxia, glutamine can be 
reductively carboxylated to generate citrate and supply lipogenic acetyl-CoA and that 
depletion of citrate or an elevated a-ketoglutarate: citrate ratio is necessary for this effect 
(Fendt et al., 2013, Gameiro et al., 2013).  We hypothesized that citrate depletion 
observed with myrAkt expression might stimulate glutamine reductive carboxylation.  
However, analysis of citrate isotopologues following exposure to [13C5 15N2]-glutamine 
revealed that glutamine continues to be oxidized in myrAkt-expressing cells and that 
little to no reductive carboxylation occurred in either high or low glucose conditions 
(Figure 14B).  On the other hand, acetyl-CoA, though significantly depleted in control 
or wt ACL-expressing cells in low glucose, retained a comparable percent enrichment 
from glucose (M+2 acetyl-CoA) when cultured in either 1 mM or 10 mM [U-13C6]-glucose 
(Figure 12C).  Moreover, in ACLY-S455D-expressing cells, both total and M+2 acetyl-
CoA resisted depletion in low glucose (Figure 12C), suggesting that even when glucose 




Hence, the data indicate that Akt promotes acetyl-CoA production and histone 
acetylation through combined effects on 1) promoting the uptake and metabolism of 
glucose and 2) promoting phosphorylation and activation of ACLY to facilitate continued 
acetyl-CoA production even when its substrate citrate is limited. 
3.2.5 Akt activation acutely promotes histone acetylation in vivo 
To directly test whether acute activation of Akt regulates histone acetylation in 
vivo, we exploited a doxycycline-inducible mouse model of breast cancer, in which 
myrAkt is activated in mammary epithelial cells upon administration of doxycycline to 
mice through the drinking water (Gunther et al., 2002). pAkt and pACLY levels 
increased with myrAkt expression, as expected (Figure 12D).  In control animals, 
relatively weak staining for AcH4 was detected in ductal epithelial cells.  Remarkably, 
however, upon induction of Akt, pronounced increases in histone acetylation were 
detected within 96 hours of doxycycline administration (Figure 12D).  On the other 
hand, another activating mark, H3K4me1, was not obviously regulated, suggesting that 
histone acetylation - not histone marks in general- may be specifically impacted by Akt 
activation.  Hence, acute activation of Akt in vivo increases global histone acetylation 
levels.   
These data indicate that activation of Akt acutely promotes histone acetylation.  
We next investigated whether Akt activation is associated with histone acetylation in 
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(A) Western blot analysis of proteins and histones from LN229 and LN229-myrAkt cells. 
Quantitation represents 5 independent experiments with LN229 4mM samples set to 1, mean +/− 
SEM (*, p ≤0.05). (B) Western blot analysis of histone acid extracts from LN229 cells stably 
expressing vector (EV), wt ACL, ACL-S455A, or ACL-S455D. Cells were treated with 1 or 10mM 
glucose for 24 hours before lysis. Quantitation represents the ratio of acetylated to total histones 
in four independent experiments with EV 10 mM set to 1, mean +/− SEM (*, p≤0.05) (C) Relative 
acetyl-CoA concentrations and percent enrichment after treatment in 1 mM or 10 mM [U-13C6]-
glucose for 20 hours, mean +/− SEM of triplicates. Total acetyl-CoA levels as well as M+2 acetyl-
CoA (enriched from glucose) were significantly suppressed (p≤0.05) in 1 mM as compared to 10 
mM glucose in EV and WT-ACL cells, but not ACL-S455D cells. (D) Control (MTB) and 
transgenic (MTB-tAkt) mice were administered doxycyclin for 96 hours (n≥5, each group). 
Immunohistochemistry was performed on paraffin-embedded mammary tissue sections. 
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(A) Western blot analysis of proteins and histones from SF188 cells with or 
without myrAkt. Quantitation represents 3 independent experiments, mean +/- 
SEM, with SF188 4mM samples set to 1. (B) LN229 and LN229-myrAkt cells were 
incubated in 1 mM glucose for indicated times. Histones were extracted and 






















































































A) Comparison of citrate levels in LN229 cells and LN229-myrAkt cells treated 
with 2mM [13C515N2 ]-glutamine and 1mM or 10mM glucose for the indicated 
times. The graph depicts total citrate normalized to total glutamate. The total of 
each metabolite was calculated as the summation of isotopologues generated 
for the metabolite. (B) Comparison of citrate isotopologues in LN229 and LN229-
myrAkt cells treated with 2 mM [13C515N2]-glutamine and 1 mM or 10 mM 
glucose for the indicated times. The graph indicates the percent of carbons 
contributed by glutamine for each isotopologue. m+4 citrate is generated 





3.2.6 Histone acetylation levels correlate with pAkt in human glioma 
The PI3K/Akt pathway is frequently activated in GBM as a result of mutations 
resulting in activation of EGFR or PI3K or loss of PTEN (Lino and Merlo, 2011).  We 
examined a diverse panel of human gliomas to determine whether AcH4 is associated 
with pAkt levels.  A total of 56 samples on a tumor tissue microarray (TMA) were 
analyzed for pAkt and AcH4 (Figure 15A).  Each tumor sample was scored in a blinded 
manner by a neuropathologist and given a combined score for percent of positive cells 
and intensity of staining (H-score) for both pAkt and AcH4.    A statistically significant 
positive correlation was found between pAkt and AcH4, indicating that Akt activation is 
associated with increased histone acetylation in human tumors (Figure 15B).  pAkt 
levels tended to increase with tumor grade, particularly in astrocytomas, although no 
significant relationship was observed between tumor grade and AcH4 (Figure 15C).  
The relationship between pAkt and AcH4 is therefore not secondary to effects of tumor 
grade.  IDH mutations occur frequently in gliomas and alter both cell metabolism and 
epigenetics (Losman and Kaelin, 2013).  Of particular relevance, IDH mutations cause 
hypermethylation of histones (Lu et al., 2012), suggesting the possibility that histone 
acetylation might be altered secondarily to methylation effects in IDH mutant tumors.  
H3K9me3 was previously shown to be elevated in IDH mutant tumors in this patient set 
(Venneti et al., 2013a), and we found no significant relationship between H3K9me3 and 
pAkt levels (not shown).  Moreover, AcH4 levels were not different between IDH wt and 












































































(A) Representative images (20X) of pAkt and AcH4 in a grade IV GBM and a grade II 
oligodendroglioma. (B) pAkt expression showed a significant correlation with AcH4 levels in 
56 human glioma samples (r=0.4721, p=0.0002). (C) pAkt and AcH4 in astrocytic tumors 
(grade IV astrocytomas = GBM) and oligodendrogliomas, mean +/−SD. (D) pAkt and AcH4 




3.2.7 Histone acetylation levels correlate with pAkt in human prostate cancer 
In human prostate tumors, significant correlations have been reported between 
levels of histone acetylation marks with tumor grade (H3K18ac and H4K12ac), as well as 
with the risk of tumor recurrence (H3K18ac, H3K9ac, H4K12ac) (Bianco-Miotto et al., 
2010, Seligson et al., 2005).  The PI3K-Akt pathway is frequently activated in prostate 
cancer due to PTEN loss or other mutations, and inhibition of Akt in the PTEN null 
prostate cancer cell lines PC-3 and C4-2 reduced overall levels of histone acetylation 
(Figure 17A).  We investigated levels of three histone acetylation marks- H3K18ac, 
H3K9ac, and H4K12ac- and their association with pAkt(Ser473) in a panel of human 
prostate tumors (Figure 16A).  The cohort consisted of patients with either metastatic 
or localized disease, with primary tumor grades ranging from 3-5 on the Gleason scale.  
Tumors were scored for both the percentage of positive cells and the intensity of 
staining.  A striking positive correlation was observed between pAkt and each of the 
histone acetylation marks (Figure 16B).  Levels of each histone acetylation mark were 
also strongly correlated with one another in tumors (Figure 17B).  Percentages of nuclei 
positive for H3K18ac were similar between patients with metastatic as compared to 
localized disease, while H3K9ac and particularly H4K12ac scored positive in a higher 
percentage of nuclei in patients with metastatic disease (Figure 17C).  H4K12ac was 
also higher in Gleason 4 and 5 tumors than Gleason 3 samples (Figure 17D). Together 
the data from human prostate cancer and glioma suggest that Akt activation is a major 




3.2.8 Histone acetylation as a predictive biomarker for therapeutic failure 
For 10 of the prostate cancer patients with localized disease, biochemical failure 
(PSA recurrence) data was available.  Strikingly, levels of histone acetylation were highly 
predictive of which patients would later exhibit biochemical failure.  The five patients 
with the lowest levels of H4K12ac, H3K18ac, and H3K9ac developed biochemical failure, 
whereas the five with the highest levels of these marks did not (Figure 16C).  These 
findings agree with those of Seligson and colleagues, showing that low levels of histone 
modifications such as H3K18ac are associated with a poor prognosis in prostate cancer 
(Seligson et al., 2005).  Within these 10 samples, the relationship between pAkt and each 
histone acetylation mark held (Figure 17E), although pAkt levels did not predict 
biochemical failure in these 10 samples (Figure 16C).  Hence, histone acetylation levels 
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(A) Representative images of H3K18ac, H3K9ac, H4K12ac, and pAkt expression 
detected by immunohistochemistry in Gleason grade 3–5, metastatic (n=25) and non-
metastatic (n=24) prostate cancer tumors. (B) H-scores were determined and 
correlations between marks determined. pAkt expression showed a significant 
correlation with: H3K18ac levels (r=0.7452, p≤0.0001); H3K9Ac (r=0.6283, p≤0.0001); 
and H4K12ac (r=0.5276, p≤0.0001). (C) Box plot showing H-scores for H4K12ac, 
H3K18ac, H3K9ac, and pAkt in prostate cancer tumors in patients who developed PSA 





Figure 17: Histone acetylation marks correlate with one another in human 


























































A) Prostate cancer cells C4-2 and PC-3 were cultured in 10mM glucose in RPMI medium 
and were either mock-treated (EtOH) or treated with Akt inhibitor for 24 hours. Whole cell 
lysates were analyzed by Western blot. B) Levels of histone acetylation marks (H3K18ac, 
H4K12ac and H3K9ac) strongly correlated with one another in tumors (H3K18ac and 
H4K12ac: r=0.58, p<0.0001, H3K18ac and H3K9ac: r=0.866, p<0.0001; H3K9ac and 
H4K12ac: r=0.6412, p<0.0001). C) Percentage distribution of positive nuclei for select 
histone marks (H3K18ac, H4K12ac and H3K9ac) between metastatic and non-metastatic 
tumors. D) Distribution of percent positivity for select histone marks (H3K18ac, H4K12ac 
and H3K9ac) in tumors based on Gleason score, mean +/ SD. E) Relationship between 
pAKT and histone acetylation marks in the 10 patients with biochemical failure data shown 





We report that oncogenic Akt activation is a key determinant of global histone 
acetylation levels in cancer cells.  We provide evidence that this occurs through Akt-
dependent metabolic reprogramming to promote high acetyl-CoA production.  Akt 
ensures continuous acetyl-CoA production even during nutrient limitation by promoting 
the phosphorylation and activation of ACLY.  To our knowledge, this is the first report 
that implicates metabolic reprogramming mediated by oncogenic activation of a signal 
transduction pathway as a major factor underlying tumor epigenomic regulation.   
Elucidating the regulation of tumor histone acetylation levels is important 
clinically, and the mechanisms that control tumor histone acetylation are currently 
poorly understood.  Our data suggest that metabolic effects contribute to determining 
histone acetylation levels in tumors.  Other relevant factors in addition to acetyl-CoA 
metabolism include levels of KATs and HDACs, as well as tumor pH.  The significance of 
global histone acetylation levels is not yet fully clear.  Several studies have examined the 
relationship between histone acetylation levels and tumor recurrence and patient 
survival in various cancer types [reviewed in (Chervona and Costa, 2012, Kurdistani, 
2007)]. Significant correlations have been shown in several studies, although high 
histone acetylation has been associated with both better and worse prognoses, likely 
reflecting differences in types of cancer, tumor grade, therapeutic approaches, and 
sample stratification.  Our data suggest that low levels of histone acetylation may predict 
poor patient outcome in prostate cancer, similar to the findings of Seligson et al 
(Seligson et al., 2005).  Further study is needed to understand how global histone 




It will be crucial to further investigate the functions of metabolic control of 
acetylation, as well as the role of ACLY levels and phosphorylation, in regulating gene 
expression and promoting tumorigenesis.  ACLY silencing is known to inhibit cancer cell 
proliferation and suppress tumor growth (Hatzivassiliou et al., 2005, Bauer et al., 2005, 
Migita et al., 2008).  While suppression of de novo lipogenesis in the absence of ACLY is 
certainly a key component of this anti-tumor effect, a growing literature indicates that 
acetylation also plays a crucial role in promoting anabolic metabolism and growth.  
Acetyl-CoA has been shown to promote growth and proliferation in yeast, through 
histone acetylation at genes involved in these processes (Cai et al., 2011).  Moreover, 
acetyl-CoA and acetylation regulate many metabolic enzymes (Guan and Xiong, 2011), 
and a role for acetyl-CoA in suppressing autophagy has also recently been uncovered 
(Eisenberg et al., 2014, Marino et al., 2014). We show here that many proliferation-
related genes are acetyl-CoA-regulated in glioblastoma cells, correlating with overall 
histone acetylation levels, as well as histone acetylation at these genes.  Thus, our study 
adds to a growing literature that implicates acetyl-CoA in providing pro-growth cues to 
the cell.  
We have focused this study on the role of the PI3K/Akt pathway in regulation of 
acetyl-CoA production and histone acetylation.  Many oncogenes and tumor suppressors 
are now recognized to regulate cellular metabolism.  Microenvironmental conditions 
such as hypoxia also potently reprogram cellular metabolism.  Moreover, in addition to 
acetyl-CoA, metabolites such as UDP-GlcNAc, S-adenosylmethionine (SAM), and a-
ketoglutarate are also required by chromatin modifying enzymes and could potentially 




is therefore conceivable that altered metabolite utilization substantially alters chromatin 
in many or most cancer cells.  
Intense effort is currently aimed at targeting both cancer cell metabolism and 
cancer epigenetics (Dawson and Kouzarides, 2012, Vander Heiden, 2011). If metabolism 
is indeed a critical mediator of cancer cell epigenetic deregulation, it is possible that 
epigenetic alterations could be reversed through therapeutics directed at metabolic 
targets.  Improved understanding of metabolic regulation of the epigenome could point 
towards contexts in which existing epigenetic therapies such as HDAC inhibitors would 
be most effective or could open doors to development of more specific therapeutics 
targeting the intersection of metabolism and epigenetics.  The finding that the PI3K/Akt 
pathway is a key determinant of histone acetylation levels in tumors represents an 
important step forward in understanding the extent to which oncogenic metabolic 





CHAPTER 4:  
ACETYL-COA COORDINATES CALCIUM-NFAT1 SIGNALING FOR CELL MIGRATION 
4.1 Introduction 
Metabolic reprogramming in cancer cells facilitates the acquisition and 
utilization of nutrients necessary for proliferation and survival within the tumor 
microenvironment, which is often nutrient-limited.  In addition to direct roles in 
metabolic processes, certain metabolites are substrates of enzymes that carry out post-
translational modifications and thus serve parallel functions as signaling molecules. 
Altered levels of such intracellular metabolites can result in distinct changes in gene 
expression, cellular differentiation, and interaction with the tumor microenvironment 
(Metallo and Vander Heiden, 2010, Pavlova and Thompson, 2016, Vander Heiden et al., 
2009, Wellen and Thompson, 2012).  
One metabolic intermediate that has emerged as a key link between metabolism, 
signaling, and the epigenome is acetyl-coenzyme A (acetyl-CoA), the acetyl donor for 
acetylation reactions (Kinnaird et al., 2016, Pietrocola et al., 2015).  Histone acetylation 
levels are highly sensitive to acetyl-CoA abundance (Cai et al., 2011, Cluntun et al., 
2015)(Chapter 3), and in many types of mammalian cells the acetyl-CoA producing 
enzyme ATP-citrate lyase (ACLY) regulates histone acetylation levels (Wellen et al., 
2009, Zhao et al., 2016, Wong et al., 2017, Covarrubias et al., 2016, Donohoe et al., 
2012).  ACLY is localized in both the cytosol and nucleus and generates acetyl-CoA from 
citrate exported from mitochondria, thus directly linking mitochondrial metabolism to 
nuclear processes such as histone acetylation and cytosolic processes such as lipid 




CoA abundance impact gene expression profiles in glioblastoma cells (Chapter 3). 
Although such changes in gene expression correlate with global histone acetylation 
levels, the specific mechanisms through which acetyl-CoA abundance impacts gene 
expression are poorly elucidated.  
Recent studies have identified roles of metabolic enzymes in gene regulation.  For 
example, acyl-CoA synthetase short-chain family member 2 (ACSS2), which uses acetate 
as a substrate to generate acetyl-CoA, is recruited to specific loci to regulate site-specific 
histone acetylation in the hippocampus to facilitate memory formation or in cells under 
nutrient stress to enable induction of autophagy and lysosome biogenesis genes(Li et al., 
2017, Mews et al., 2017).  ACSS2 has also been shown to be required for acetylation of 
the transcription factor HIF-2a (Xu et al., 2014).   
Among genes responsive to acetyl-CoA abundance in glioblastoma cells are many 
genes involved in cell adhesion, extracellular matrix (ECM) interaction, cytoskeleton, 
and integrin signaling (Chapter 3). The most common brain tumor, glioblastoma (GBM), 
is highly invasive, limiting the efficacy of surgical resection (Furnari et al., 2007, 
Jhanwar-Uniyal et al., 2015).  In this study, we aimed to define the specific mechanisms 
through which acetyl-CoA abundance regulates expression of cell adhesion and 
migration genes, since such insights could suggest new therapeutic strategies to limit the 
invasive characteristics of this lethal cancer. We identified NFAT1 as a key acetyl-CoA-
responsive transcription factor that promotes glioblastoma cell adhesion to the ECM and 
migration.  Unexpectedly, we found that acetyl-CoA abundance impacts NFAT nuclear 




al., 2015).  These data identify a link between cellular metabolism and gene regulation 
that modulates cancer cell phenotypes.  
4.2 Results 
4.2.1 Acetyl-CoA availability regulates expression of genes involved in cell migration 
and adhesion in glioblastoma cells.  
Histone acetylation levels decline when glucose is limited, correlating with acetyl-
CoA abundance, and can be restored upon supplementation of acetate, which enters the 
cell and is directly converted to acetyl-CoA by acetyl-CoA synthetase enzymes (ACSS1-3).  
In the previous chapter, we profiled gene expression in high and low glucose conditions, 
in the presence and absence of acetate (Figure 4). Among gene sets enriched in “acetyl-
CoA-high” conditions (enriched in both high glucose and low glucose plus acetate) were 
cell adhesion, migration, and cytoskeleton pathways (PANTHER: Integrin signaling 
pathway; KEGG: Regulation of actin cytoskeleton; KEGG: Cell adhesion molecules; 
REACTOME: Integrin cell surface interactions; KEGG: ECM-receptor 
interaction)(Figure 4). Expression patterns for select genes within these sets were 
validated by qPCR (Figure 18A). H3K27 acetylation (H3K27ac) correlated with gene 
expression at glucose- and acetate-regulated genes, as shown by ChIP-qPCR (Figure 
19A).  To test if cell migration was functionally impacted under these conditions, we 
employed wound healing and transwell migration assays. In both, cell migration was 
impaired in low glucose and rescued with acetate supplementation (Figure 18B, C). 
Importantly, acetate rescued cell migration without altering doubling time (Figure 4), 




 Integrin-mediated adhesion to the extracellular matrix (ECM) is a crucial 
component of cancer cell migration and invasion (Pickup et al., 2014).  To test the impact 
of acetyl-CoA abundance on glioblastoma cell adhesion to the ECM, we employed a 
brain-inspired biomaterial platform comprised of 50% fibronectin, 25% vitronectin, 20% 
tenascin C, and 5% laminin (Barney et al., 2015). After incubating cells in high or low 
glucose, with or without acetate supplementation, cells were seeded onto the ECM and 
their adhesion was recorded over time. Both glucose and acetate enhanced cell adhesion 
to the brain ECM (Figure 18D). Enhanced adhesion by glucose and acetate was also 
observed using a simplified adhesion assay with fibronectin only, and these findings 
were consistent in three other glioblastoma cell lines tested (Figure 18E-G).  To test 
whether the timing for acetyl-CoA dependent cell adhesion is consistent with a 
transcriptional process, we performed a time course analysis of adhesion following 
glucose and acetate supplementation. Cells were incubated overnight in low glucose and 
then high glucose or acetate added back and adhesion examined. Improved capacity to 
adhere to fibronectin was observed beginning 4 hours after glucose or acetate addback 
and was most pronounced after 24 hours (Figure 18H), consistent with a role for gene 
transcription rather than an acute signaling event.  
Regulation of adhesion and migration by glucose and acetate could be directly 
reliant on acetyl-CoA itself, or indirectly mediated through a metabolic pathway that 
employs acetyl-CoA, such as fatty acid, cholesterol, or hexosamine synthesis.   For 
example, fatty acids are required for cell migration by contributing to invadopodia 
formation and lipid rafts (Scott et al., 2012, Byon et al., 2009). Fatty acid 
supplementation, however, was unable to restore adhesion under low glucose conditions 




isoprenoids, which also contributes to migration (Mullen et al., 2016), failed to 
significantly rescue adhesion (Figure 19C).  N-acetyl-glucosamine (GlcNAc), which 
rescues the hexosamine pathway and is important for receptor membrane localization 
(Wellen et al., 2010), resulted in a modest enhancement (Figure 19C). This suggested 
that the ability for cells to generate lipids, sterols, and glycan-chain was not as limiting as 
acetyl-CoA itself. Acetate can also be converted to acetyl-CoA in mitochondria, and 
consistent with this, citrate levels were suppressed in low glucose and partially restored 
by acetate supplementation (Figure 19D).  Moreover, pyruvate supplementation 
enhanced cell adhesion to a similar extent as acetate under low glucose conditions 
(Figure 19E). Glucose, acetate, and pyruvate all can supply mitochondrial acetyl-CoA to 
support citrate production and use in the TCA cycle.  Mitochondrial citrate can also be 
exported for ACLY-dependent acetyl-CoA production in the cytosol and nucleus. 
Notably, inhibition of the lysine acetyltransferase p300 using C646 suppressed the 
effects of glucose and acetate in enhancing H3K27ac levels and cell adhesion (Figure 
19F, G), further supporting roles acetyl-CoA as a signaling molecule. Collectively, these 
data indicate that glioblastoma cell adhesion and migration is impaired when 
intracellular acetyl-CoA levels are low.   
4.2.2 Nutrient-regulated cell adhesion and migration requires ACLY.  
As evidenced by the increase in citrate after the addition of acetate, we next asked 
whether ACLY is required for nutrient-dependent adhesion and migration. Upon 
silencing of ACLY, both wound healing and adhesion to fibronectin were impaired 
(Figure 20A, B). Similarly, pharmacological inhibition of ACLY potently suppressed 




related genes (Figure 20B, C, and Figure 21A). Nutrient-dependent adhesion and 
expression of ITGA2B were also suppressed upon genetic deletion of ACLY in LN229 
cells (Figure 20E, F).  Moreover, xenograft tumor growth was markedly impaired in 
the absence of ACLY (Figure 21B, C), and several adhesion- and migration-related 
genes exhibited lower expression in tumors generated from ACLY-deficient cells (Figure 
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 (A) Relative mRNA levels of acetyl-CoA up-regulated genes in LN229 cells. Significance of acetate 
treated over 1 mM glucose denoted # (#, p<0.05; ##, p<0.01). Significance of 10 mM glucose treated 
over 1 mM glucose denoted * (**, p<0.01; ***, p<0.001). (B) Wound healing assay in LN229 cells. (***, 
p<0.001, ****, p<0.0001). Right panel: Lines indicate boundary of scratch. Photos captured at 0 hours 
and after 24 hours. (C) Transwell migration of LN229 across 8.0 μm polycarbonate membrane. (*, 
p<0.05; **, p<0.01). Right panel: cells were stained with Hoechst and photos were captured 24 hours 
after seeding. (D) Adhesion quantified on biomaterial platform with ECM components of the brain. Area 
covered by cells were measured over time. Turkey Post Test *, p<0.05. (E-G) Relative adhesion to 1% 
fibronectin after 24 hours of indicated treatments in (E) LN18, (F) U87, and (G) U251 cells ** p<0.01,*** 
p<0.001, **** p<0.0001. (H) LN229 cells were treated after overnight starvation. Quantification of 
adhesion to 1% fibronectin after indicated hours of treatment ** p<0.01,*** p<0.001, **** p<0.0001. For 
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(A) H3K27ac analysis of several regions of indicated genes. Significance of 
acetate treated over 1 mM glucose denoted with # (#, p<0.05; ##, p<0.01). 
Significance of 10 mM glucose treated over 1 mM glucose denoted with * (*, 
p<0.05; **, p<0.01; ***, p<0.001). (B-C) Relative adhesion after 24 hours of 
treatment (*, p<0.05; **, p<0.01; ****, p<0.0001). (D) relative amount of citrate 
detected by LCMS, normalized to U-13C-citrate as internal control (*citrate) 
Mean, error bars represent SD triplicates (p<0.05). (E) Relative adhesion to 
1% fibronectin after 24 hours of treatment (*, p<0.05; **, p<0.01; ***, 
p<0.001). (F) Detection of acetylation as determined by western blot after 24 
hours of indicated treaments. (G) Relative adhesion onto 1% fibronectin after 
24 hours of treatment with C646 or vehicle control (DMSO) (***, p<0.001). 
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A) Wound healing assay in U251 with stable knockdown of ACLY(*, p<0.05) (B) Relative adhesion 
in U251 cells with stable knockdown of ACLY. (**, p<0.01; ***, p<0.001) (C) Transwell migration of 
LN229 cells after treatment with ACLi or vehicle; no FBS is a control. (**, p<0.01).  All conditions 
were in 10 mM glucose. (D) Relative mRNA expression of acetyl-CoA regulated genes in U251 cells 
treated with 50 μM ACLY inhibitor (ACLi; BMS303141) in 10 mM glucose. (***, p<0.001; ****, 
p<0.0001). (E) Relative adhesion in two different ACLY-KO clones (sg3.6 and sg3.8) on 1% 
fibronectin. Parental cells (LCV2) were infected with Cas9 but without guide RNA. (**, p<0.01; ****, 
p<0.0001). (F) Relative expression of ITGA2B in cells described in panel E (*, p<0.05; **, p<0.01).  
(G) Relative mRNA expression of acetyl-CoA up-regulated genes in xenograft derived tumors (*, 



























































(A) Relative adhesion in U251 cells on 1% fibronectin after 24 hours with 50 µM ACLYi. (**, p<0.01). 





4.2.3 Cellular adhesion and migration genes are regulated by NFAT family 
transcription factors.  
While expression of cell migration and adhesion genes correlates with histone 
acetylation (Figure 18A and Figure 19A), we postulated that specificity of acetyl-CoA 
dependent gene expression might be achieved through regulation of one or more 
transcription factor.  To gain initial insight into transcription factors that might be 
responsive to acetyl-CoA abundance, we queried the Broad Institute molecular 
signatures database (MSigDB) to identify top enriched transcription factor motifs 
(Subramanian et al., 2005, Mootha et al., 2003). The NFAT binding consensus motif 
TGGAAA(Badran et al., 2002) was the most highly enriched transcription factor motif 
within 2 kb upstream and downstream of the TSS of “acetyl-CoA up” genes (Figure 
22A, and Figure 23A, B).  
NFAT isoforms 1-4 are calcium-responsive transcription factors involved in a 
wide range of cellular processes in different cell types (Muller and Rao, 2010, Mancini 
and Toker, 2009). Notably, substantial evidence links NFAT to the regulation of cell 
migration and invasion in cancer (Qin et al., 2014), including in glioblastoma 
(Chigurupati et al., 2010, Tie et al., 2013, Wang et al., 2015).  Ca2+ homeostasis is tightly 
controlled in the cell. When Ca2+ is released from endoplasmic reticulum stores into the 
cytosol, calcium-sensitive calmodulin activates the phosphatase calcineurin, which 
dephosphorylates NFAT. Dephosphorylation exposes the nuclear localization signal that 
allows NFAT to enter the nucleus and bind to its canonical motif (Muller and Rao, 2010, 
Mancini and Toker, 2009). NFAT requires the coactivator p300 for its transcriptional 




acetyl-CoA-responsive genes. However, the majority of NFAT regulated genes in glioma 
have not been defined, nor is NFAT known to be responsive to acetyl-CoA availability.  
To investigate whether NFAT is involved in acetyl-CoA-dependent adhesion, we 
inhibited calcineurin with cyclosporine A (CsA) (Schreiber and Crabtree, 1992). CsA 
potently suppressed cell adhesion to fibronectin in the presence of either glucose or 
acetate (Figure 22B and Figure 23C). Reciprocally, we tested whether increasing 
cytosolic calcium could promote cell adhesion. Treatment of cells with ionomycin for 4 
hours rescued cell adhesion under low glucose conditions, as well as after treatment with 
ACLYi (Fig 3C and 3D). Using quantitative PCR, we determined that NFAT1 (NFATC2) 
is the most highly expressed NFAT isoform in LN229 cells (Figure. 23D). RNA-
mediated silencing of NFAT1 (Figure 23E) suppressed both canonical NFAT target 
genes such as PTGS2, as well as selected “acetyl-CoA-up” genes predicted to be NFAT 
targets (Figure 22E and Figure 23F). Additionally, NFAT1 silencing reduced wound 
healing and adhesion (Figure 22G). Thus, is most likely that NFAT1 is required for 





Figure 22: The transcription factor NFAT1 mediates acetyl-CoA dependent 


























































































































































































(A) Gene set enrichment analysis (GSEA) of acetyl-CoA up-regulated genes. (B) LN229 
cell adhesion onto 1% fibronectin after 24 hours of 10 μM cyclosporin A (CsA) or vehicle 
control.(*p<0.05; **, p<0.01; ***p<0.001). (C) LN229 cell adhesion onto 1% fibronectin 
after 20 hours of nutrient treatment followed by 4 hours of treatment with 0.5 μM 
ionomycin or vehicle control. (****, p<0.0001) (D) Relative adhesion after 20 hours of 
treatment with ACLYi followed by 4 hour of treatment with 0.5 μM ionomycin or vehicle 
control. *, p<0.05; ** p<0.01. (E) Relative mRNA expression of acetyl-CoA up-regulated 
genes after short-hairpin mediated knockdown of NFAT1 in LN229 cells. Representative 
genes from list generated in from GSEA in panel A. (F) Relative adhesion onto 1% 
fibronectin after 24 hours of indicated nutrient conditions after knockdown of NFAT1 in 
LN229 cells (***, p<0.001). (G) Wound healing assay in LN229 cells after knockdown of 




Figure 23: NFAT1 is the top predicted transcription factor to regulate acetyl-























TGGAAA_V$ NFAT _Q4_01 1.55E-26
CTTTGT_V$ LEF1 _Q2 1.93E-23
GGGTGGRR_V$ PAX4 _03 3.81E-21
GGGAGGRR_V$ MAZ _Q6 6.47E-20
TTGTTT_V$ FOXO4 _01 8.49E-20
CAGGTG_V$ E12 _Q6 1.59E-19
AACTTT_UNKNOWN 2.96E-19
GGGCGGR_V$ SP1 _Q6 1.55E-16
CTGCAGY_UNKNOWN 8.91E-16
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(A) Top motifs predicted to regulate acetyl-CoA genes. (B) Heatmap representation of 
genes identified in Figure 22A. (C) Relative adhesion onto 1% fibronectin after 24hour 
treatment with CsA (20µM). (****, p<0.0001). (D) Relative mRNA levels of each NFAT 
family member in LN229. (E) Representative image of immunofluorescent staining of 
NFAT1 in red demonstrating knockdown efficiency. (F) Relative adhesion onto 1% 
fibronectin after knockdown of NFAT1 using previously published hairpin sequence 




4.4.4 Calcium dynamics and NFAT1 localization is acetyl-CoA dependent.   
Since ionomycin rescued cell adhesion in low glucose (Figure 22C), acetyl-CoA 
may be acting upstream of calcium release to control NFAT. To investigate if acetyl-CoA 
impacts calcium dynamics, we sought to visualize and measure cytoplasmic calcium 
using an ultra-sensitive protein calcium sensor, GCaMP6f (Chen et al., 2013a). Cells were 
starved overnight in 1 mM glucose and then medium replaced, containing 1 mM glucose, 
10 mM glucose, or 1 mM glucose + 5 mM acetate.  Calcium bursts were monitored over 
time, and both glucose and acetate were found to enhance the frequency of Ca2+ release 
(Figure 24A). These “Ca2+ bursts” are thought to promote local focal adhesion proteins 
disassembly which is required for migration (Tsai and Meyer, 2012, Wei et al., 2009).  
Notably, previous literature demonstrated that glucose promotes 
Ca2+-NFAT signaling, via phosphoenolpyruvate (PEP)-dependent inhibition of SERCA 
reuptake of cytosolic calcium (Ho et al., 2015). In the glioblastoma cells, high glucose 
raised PEP levels, but acetate did not, (Figure 25), suggesting that acetate impacts Ca2+ 
homeostasis via a distinct mechanism.  
If acetyl-CoA abundance impacts intracellular Ca2+, it would be expected to 
promote NFAT1 dephosphorylation and nuclear localization. Indeed, using 
immunofluorescent imaging, we observed that NFAT1 nuclear localization is reduced 
under low glucose conditions and rescued in the presence of acetate (Figure 24B, 
24C).  Ionomycin treatment induced a shift in NFAT mobility in gel, consistent with 
reduced phosphorylation (Figure 24D).  Both glucose and acetate similarly increased 
NFAT mobility, and no further effect was observed in the presence of ionomycin (Figure 




nuclear localization was restored upon reintroduction of murine ACLY (Figure 26B, 
26C). Biochemical inhibition of ACLY also reduced NFAT mobility (consistent with 
hyperphosphorylation) and suppressed NFAT nuclear localization (Figure 24E, F).  In 
the presence of ionomycin, ACLY inhibition failed to reduce NFAT mobility (Figure 
24F), consistent with ACLY acting upstream of calcium release. The addition of a 
phosphomutant (Wang, J Pathol 2009) constitutively active NFAT1 rescued adhesion 
under low glucose compared to exogenous WT-NFAT1. (Figure 24G).  Together, these 
data indicate that acetyl-CoA abundance facilitates cell adhesion and migration in 
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(A) Quantification of fluorescent spikes after nutrient addback. At least 116 cells counted per condition. 
Blinded scoring of number of spikes per field per cell. **, p<0.01; *,p<0.05. (B) Immunofluorescent 
detection of endogenous NFAT1 localization in LN229 cells.  (C) Quantification of NFAT1 detected in the 
nucleus as percentage per field. **, p<0.01 (D) Western blot of phosphorylation state of exogenously 
expressed HA-tagged NFAT1 after 16 hours of treatment followed by 15 minutes of treatment with 
ionomycin (Iono) or vehicle before harvest. (E) Western blot depicting NFAT1 localization after cellular 
fractionation. Cells were treated for 24 hours in 10 mM glucose with indicated concentrations of ACLYi or 
with ethanol vehicle control. (F) Western blot of phosphorylation state of exogenously expressed HA-
tagged NFAT1 after 16 hours of treatment in 10 mM glucose and indicated concentrations of ACLYi 
followed by 15 minutes of treatment with ionomycin or vehicle before harvest.  (G) Relative adhesion in 





Figure 25: PEP concentrations are regulated by glucose and cannot be 


















































































































sg 3.6 + ACLY
A. B.
DAPI NFAT1 Overlay
(A) Immunofluorescent detection of endogenous NFAT1 localization in LN229 and LN229 
sgACLY cells (clone 3.6) with or without expression of CRISPR resistant mouse ACLY.  (B) 
Quantification of NFAT1 detected in the nucleus as percentage per field in LN229 and 
LN229 sgACLY cells (clones 3.6 and 3.8). * denotes significance of knockout compared to 
LN229 (**, p<0.01, ****, p<0.0001). # denotes significance of knockout compared to ACLY 





A growing body of work demonstrates that metabolism can regulate cellular 
decisions. These decisions are made in part through the regulation of gene expression. In 
these studies, we chose to alter glucose and acetate in cell culture media to determine the 
effects of acetyl-CoA abundance in the cell on the expression of genes involved in cell 
migration and adhesion in glioblastoma cells. We found that the expression of these 
genes is in part mediated through the regulation of Ca2+-NFAT1 signaling. While NFAT 
has been previously shown to be regulated in response to glucose availability (Ho et al., 
2015, Koenig et al., 2010, Lawrence et al., 2002), acetyl-CoA as a product of glucose 
metabolism has not been previously linked to Ca2+ homeostasis or NFAT function.  
Calcium is a critical signaling molecule that needs to be tightly controlled. In 
non-excitable cells and in cancer, changes in cytosolic calcium are transient and tend to 
follow an oscillatory pattern (Dupont et al., 2011). These dynamics are important for 
signaling and activate important downstream proteins in the nucleus. Both calcium 
oscillations and NFAT transcription factors have established roles in cancer cell 
migration and invasion (Qin et al., 2014, Cui et al., 2017). In glioblastoma, Ca2+ 
oscillations trigger migration by modulating focal adhesion dynamics (Giannone et al., 
2002).  These calcium oscillations are controlled in part by store-operated calcium 
channel proteins, STIM1 and Orai1, which were found to be critical for glioblastoma 
invasion (Motiani et al., 2013). Similarly, TRPC6, a receptor-activated calcium channel 
in the cell membrane, expression increases under hypoxia and promotes elevated 
intracellular calcium and NFAT activation; knockdown of TRPC6 or NFAT inhibition 




Consistently, inhibition of IP3R-mediated Ca2+ release, with caffeine, reduced 
glioblastoma cell migration and extended survival in a mouse glioblastoma xenograft 
model (Kang et al., 2010).   
The deregulation of calcium oscillations by metabolism is underexplored. The 
current study identifies that high acetyl-CoA abundance promotes Ca2+-NFAT signaling. 
Dysfunctional calcium homeostasis is proposed to be associated with metabolic 
pathological conditions (Arruda and Hotamisligil, 2015), and our data suggests that 
cancer metabolism can feed forward to promote transient calcium release that can signal 
downstream to initiate many processes, such as NFAT nuclear localization. NFAT 
overexpression and aberrant nuclear localization have been reported in other cancers, 
such as pancreatic cancer (Koenig et al., 2010, Buchholz et al., 2006); thus, it is tempting 
to speculate that our model may hold true in a broad range of solid tumors with 
demonstrated Ca2+-NFAT signaling. Future experiments will be needed to elucidate the 
precise mechanisms through which acetyl-CoA promotes calcium dynamics for NFAT 
activation. 
Acetyl-CoA continues to provide a layer of regulation on epigenetics and gene 
expression. In establishing acetyl-CoA regulation of glioblastoma cell migration, our 
study provides a previously unrecognized link between metabolism and calcium 
homeostasis. We are only beginning to understand how tumor metabolism signals to the 




 CHAPTER 5:  
CONCLUSIONS/FUTURE DIRECTIONS 
5.1 Conclusions 
Cancer cells exhibit substantial epigenetic alterations that contribute to the 
acquisition of all hallmarks of cancer (Jones and Baylin, 2007, Hanahan and Weinberg, 
2011). In this thesis, we explored how extensively metabolic reprogramming contribute 
could contribute to this epigenetic deregulation.  Several studies over the past several 
years provide compelling evidence that acetylation of histones is dependent on the 
availability of acetyl-CoA [reviewed in (Kinnaird et al., 2016). Prior to the work 
presented in this thesis, the field of cancer metabolism and epigenetics speculated on the 
possibility that concentrations of acetyl-CoA could be limiting and the concentrations 
could impact histone acetylation. In this work, we present evidence that mammalian 
concentrations of acetyl-CoA are between 6-13 µM in the cell and the ratio of acetyl-
CoA:CoA are regulated dynamically by glucose availability, which impacts overall histone 
acetylation levels.  
We further explored the oncogenic control of acetyl-CoA as a major contributor 
to deregulated global histone acetylation. We found that constitutive activation of the 
PI3 kinase-AKT pathway promotes elevated histone acetylation, both in vitro in cancer 
cell lines and in vivo in 2 different mouse models. Remarkably, although histone 
acetylation levels are regulated by glucose, phosphorylation of ACLY downstream of AKT 
allows histone acetylation to be sustained during glucose limitation (Figure 12, Figure 
27). Such a mechanism could potentially enable tumor cells to maintain histone 




histone acetylation levels were found to correlate significantly with pAKT(Ser473) in 
human gliomas and prostate tumors (Figure 15, Figure 16).  
Secondly, we addressed the impact of acetyl-CoA availability on tumor-
promoting phenotypes. In glioblastoma cells, genes favored in the presence of high 
acetyl-CoA include those with roles in cell cycle, DNA replication, and cell migration 
(Figure 4). During glucose limitation, supplementing cells with acetate (increasing 
acetyl-CoA levels) stimulated expression of these genes, promoted migration (Figure 
18), but did not promote proliferation unless other glucose-dependent metabolites were 
provided (Figure 4). Thus, acetyl-CoA may provide a pro-growth signal to the cell by 
regulating relevant gene expression programs. Notably, elevated histone acetylation is 
observed upon oncogene activation in mice prior to the appearance of tumors (Figure 
8). Studies exploring the possibility that oncogene-induced metabolic regulation of 
histone acetylation might promote a favorable epigenetic context for malignant 
transformation are currently in progress in the lab. 
The results from the work in Chapter 3 led us to further investigate mechanisms 
of acetyl-CoA dependent gene expression.  Like the growth-related genes, histone 
acetylation near the promoter regions of several migration genes were significantly 
higher under conditions that promoted acetyl-CoA formation (Figure 5). But to 
understand whether other forms of transcriptional regulation are at play, we investigated 
our acetyl-CoA gene set to uncover potential transcription factors that might control cell 
migration. Notably, NFAT family proteins were predicted to regulate our gene set 
(Figure 22).  Many studies demonstrate NFAT proteins in tumorigenesis and tumor cell 
migration (Mognol et al., 2016, Muller and Rao, 2010). Furthermore, glioma samples 




acetyl-CoA conditions can reduce NFAT nuclear accumulation and mechanistically, this 
is through loss of acetyl-CoA regulation of calcium oscillations. Our study points to an 
undescribed metabolic regulation of NFAT nuclear localization and also connects 
together previous studies that have implicated acetyl-CoA (Chen et al., 2015), NFAT 
(Mancini and Toker, 2009), and calcium independently to cell migration (Chen et al., 
2013b) (Figure 28).  
Of note, we find a requirement for ACLY to initiate cell adhesion and migration 
and provision of acetate in ACLY-deficiency does not rescue adhesion. Others have 
observed similar phenomena that acetate induction of T cell activation requires ACLY 
(Balmer et al., 2016). Indeed, when 13C-acetate was monitored in human patients with 
glioblastoma by 13C- NMR, glioma cells incorporated acetate derived carbons into the 
TCA cycle metabolites, including citrate. In ACLY-deficient settings, cell proliferation 
(Zhao et al., 2016) and homologous recombination DNA damage repair (Sivanand et al., 
2017), acetate is not able to full compensate for the loss of the phenotype. Reasons for 
why acetate cannot rescue certain phenotypes under ACLY-deficiency remains to be 
explored.  
Acetyl-CoA and acetylation thus represent crucial components of the cell's 
nutrient-sensing repertoire. The functional consequences of high acetyl-CoA might be 
diverse depending on the cell-type and future studies will need to be done to address 
how broadly the described mechanisms regulate cancer cell phenotypes. Importantly, 
these studies provide evidence for how nutrient availability is assimilated to coordinate a 





Figure 27: AKT promotes tumor cell histone acetylation  
Model for findings in Chapter 3: Oncogenic AKT expression promotes elevated histone 




Figure 28: Acetyl-CoA promotes adhesion and migration through histone 












Model for findings in Chapter 4: acetyl-CoA availability via ACLY and ACSS2 increases 
histone acetylation at adhesion and migration related genes and also increases cytosolic 
calcium to allow NFAT1 to localize in the nucleus. Collectively, this results in gene 




5.2 Future Directions 
5.2.1 Acetyl-CoA and organelle calcium-store crosstalk? 
Our data points to acetyl-CoA production being upstream of calcium signaling. 
The addition of ionomycin, an artificial stimulation of calcium release, can rescue 
adhesion in acetyl-CoA depleted conditions.  It remains to be explored how acetyl-CoA 
communicates with organelles for calcium release into the cytosol. The mitochondria and 
the endoplasmic reticulum (ER) are two potential sources of intracellular calcium.  
Many studies on mitochondria calcium regulation have been linked to cell 
migration [reviewed in (Paupe and Prudent, 2017)]. Acetate uptake by the cell under low 
glucose conditions may reduce mitochondria calcium overload. Mitochondrial matrix 
Ca2+ overload enhances generation of reactive oxygen species, triggers the permeability 
transition pore, and releases cytochrome c, which ultimately causes cell apoptosis. 
Notably, calcium is required for proper TCA enzymatic reactions [reviewed in (Denton, 
2009)]. Perhaps acetate supplementation supports the balance of calcium in the 
mitochondria, preventing accumulation of calcium in the mitochondria and presumably 
more in the cytosol. MICU1 is the molecular gatekeeper preventing mitochondria Ca2+ 
overload (Mallilankaraman et al., 2012). In endothelial cells, silencing MICU1 impaired 
cell migration by scratch assay and a basal increase of mitochondrial Ca2+. Experiments 
designed to test whether MICU1 knockdown impedes acetate rescue of cell migration 
could help us understand this delicate relationship between acetyl-CoA and 




Alternatively, acetyl-CoA could communicate with the endoplasmic reticulum 
(ER). This relationship is plausible because: 1) the ER largest store of calcium in the cell 
and 2) the ER membrane has an acetyl-CoA transporter (AT-1). AT-1 deficient animals 
develop early onset of neurological problems, suggesting that changes in ER acetyl-CoA 
homeostasis is linked to disease (Peng et al., 2014). Perhaps nutrient-derived acetyl-CoA 
is required for rapid nutrient-sensitive acetylation in the ER that allows for release of 
calcium. Acetyl-proteomics analysis after subcellular fractionation of organelles from 
cells given a short treatment of U-13C-glucose could help us identify proteins that are 
acetylated in a nutrient dependent manner and related to calcium regulatory processes.  
 Notably, it was previously reported in T cells that glycolysis supports calcium 
signaling through production of PEP, which inhibits the cytosolic calcium uptake 
transporter sarcoplasmic endoplasmic reticulum calcium antiporter (SERCA) (Ho et al., 
2015). PEP is proposed to inhibit SERCA by oxidizing cysteine 675, a known 
modification that reduces SERCA activity (Sharov et al., 2006). This allows for sustained 
calcium release (Ho et al., 2015). Similar to PEP, acetate itself might also promote 
cysteine oxidation on SERCA. We would examine the redox state of the cell under low 
glucose + acetate conditions to further delineate mechanisms for acetate regulation of 
calcium. If we see an effect by acetate, knockdown of ACSS1 and/or ACSS2 would further 
confirm the effects were dependent on acetate derived acetyl-CoA.  
5.2.2 Defining nutrient sensitive histone acetylation in glioblastoma   
In low glucose conditions, acetyl-CoA levels decrease and become limiting for 




reduction in global and promoter-specific histone acetylation. Importantly, 
supplementation of acetate can rescue intracellular pools of acetyl-CoA, histone 
acetylation, and restore growth promoting gene expression. These findings suggest that 
acetyl-CoA provides a layer of regulation of gene expression in tumors. However, 
whether the histone acetylation occurs at relevant regions of the genome and plays a role 
in the transcription isn’t clear.  Determination of the precise location nutrient-sensitive 
acetylation at a genome-wide level could further inform us of functional consequences of 
high histone acetylation.  
Few studies have completed a full characterization of metabolite availability and 
paired it with assessment of genome-wide changes. As mentioned in the introduction, 
histone acetylation in yeast displayed nutrient regulated histone acetylation. Of note, 
while H3K9ac appeared at promoters concurrently with expression as determined by 
RNA-seq, H3K14ac and H4K5ac presented at the promoters about an hour before the 
RNA peak appeared (Kuang et al., 2014), suggesting that different KATs may respond to 
different levels of acetyl-CoA.  In cancer, methionine restriction indeed reduced 
H3K4me3 globally (Mentch et al., 2015). Pairing the information on H3K4me3 as 
determined by ChIP-seq to RNA-seq expression data, the authors found that the regions 
of the genome that responded to methionine corresponded with changes in gene 
expression from RNA-seq in colon cancer cells. These changes were 2 Kb upstream and 
downstream of the TSS. However, neither of these studies reported the number of gene 
promoters that were sensitive and the degree of overlap with changes in gene expression. 
How much histone acetylation is part of gene regulation versus buffering (McBrian et al., 




We could contribute to this question through using our glioblastoma cells, where 
we have already defined a system where acetyl-CoA availability can be controlled. Future 
work should expand on identifying the genomic regions that are sensitive to acetyl-CoA 
in this system. Traditional ChIP-seq methods do not allow for direct comparison of 
signal amplitude between samples. In order to achieve quantitative comparisons of 
histone acetylation genome-wide, this work should be completed using ChIP-Rx 
(Orlando et al., 2014), which will identify graded epigenomic changes following 
treatment.  These studies will help us understand the consequences of histone 
acetylation and understand how transient these programs are.  
Furthermore, definition of nutrient sensitive sites on the genome may offer some 
insight on specificity of glucose versus acetate dependent histone acetylation. It is 
curious why mammalian cells evolved with the expression of two very important nuclear-
cytoplasmic acetyl-CoA producing enzymes, ACLY and ACSS2.  As mentioned in the 
introduction, both enzymes are highly relevant in many different types of cancer and 
both contribute to histone acetylation under various conditions [reviewed in (Carrer and 
Wellen, 2015, Kinnaird et al., 2016)]. In fact, nuclear ACSS2 binds near regions of 
H3K9ac, H5K4ac, and H4K12ac and is required for memory formation in the 
hippocampus (Mews et al., 2017). Our studies could complement these findings in a 
cancer setting.  
5.2.3 Therapeutic implications 
Targeting ACLY will be challenging as cells will likely find alternative sources of 




rescue cell migration. However, it is encouraging that in ACLY-knockout cells, acetate 
does is not sufficient to rescue adhesion, indicating that there may be conditions that 
allow for ACLY to be targeted therapeutically. It is possible that development of a better 
ACLY inhibitor can be used to slow down glioma cell migration in combination with 
current glioblastoma therapies designed to slow down cell growth. Additionally, 
targeting NFAT regulated genes related to cell migration may provide another method to 
target glioblastoma. Lastly, it would be interesting to understand whether therapeutics 
targeting acetyl-CoA metabolism also impact chromatin modifications and perhaps can 
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